HONG KONG, Jul 6, 2020 - (ACN Newswire) - VPower Group International Holdings Limited ("VPower Group") a leading DPG station owner and operator in Asia announced today that it has strengthened its market presence in Sri Lanka with two power stations commencing commercial operation recently.
Located in Galle and Pallekele, respectively, of Sri Lanka, the two power stations were built on a fast-track basis with a total installed capacity of 38.8MW. They are connected to the national grid via respective regional substations.
Sri Lanka has been striving to increase its generation capacity to meet the rising electricity demand, and VPower Group is keen to provide the country with reliable distributed power solutions. Since VPower Group entered into the power market of Sri Lanka in mid-2019, it has established a project portfolio of an aggregated installed capacity reaching 100MW locally.
About VPower Group International Holdings Limited
Headquartered in Hong Kong, VPower Group is an integrated expert in distributed power generation (DPG). It principally engages in power system integration (SI) business, covering designing, integrating and sale of gas-fired and diesel-fired engine-based gen-sets and power generation systems, and Investment, Building and Operating (IBO) business, involving investing in, building and operating distributed power stations to supply reliable electricity. It is now a leading distributed power station owner and operator in Asia.
Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com
source http://www.acnnewswire.com/press-release/english/60049/
7/6/20
マツダ、後付けの「ペダル踏み間違い加速抑制装置」を発売
本装置は、車両前後に装着した超音波センサーで前方または後方約3m以内にある壁などの障害物を検知した場合、ブザー音と室内に取り付けたインジケータで注意喚起をします。それでもブレーキペダルと間違えてアクセルペダルを強く踏み込んだ場合には、加速を抑制し衝突時の被害軽減に貢献します*4。
また後退時には、壁などの障害物を検知していない時でも、時速約5km以上でアクセルペダルを踏んだ場合、ブザー音とインジケータで注意喚起をし、加速を抑制して衝突の回避や被害の軽減を図ります*4。
今回発売する後付けの「ペダル踏み間違い加速抑制装置」は、マツダ純正用品で、サポカー補助金*5の対象になります。
近年、駐車場などでのペダル踏み間違いによる事故の割合が増えてきています。このような状況に対して、マツダは独自の安全思想であるマツダ プロアクティブ セーフティ*6にもとづいた安心安全技術を搭載した車種を拡充し、クルマに乗る人が安心して運転を楽しめることを目指してきました。
さらに、後付けの「ペダル踏み間違い加速抑制装置」の導入により、現在販売中の車種だけではなく、「デミオ」「ベリーサ」を長くお乗りいただいているお客さまにも、より安心して運転を楽しんでいただけるようになります。
マツダは、クルマ本来の魅力である「走る歓び」によって、美しい「地球」と心豊かな「人」・「社会」を実現し、人の心を元気にすることにより、お客さまとの間に特別な絆を持ったブランドになることを目指してまいります。
本リリースの詳細は下記をご参照ください。
https://newsroom.mazda.com/ja/publicity/release/2020/202007/200706a.html
概要：マツダ株式会社
詳細は www.mazda.co.jp をご覧ください。
Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02
NEC、日本・グアム・オーストラリアを結ぶ光海底ケーブル「JGA」の北セグメントの建設を完了
JGAは、最新の光波長多重伝送方式を採用した総延長距離約9,500kmの光海底ケーブルで、アルカテル・サブマリンネットワークス(ASN)とNECが共同で建設を請負しました。ASNが担当する南セグメント(グアム・オーストラリア間、約7,000km)はすでに建設を完了し、本年3月にRAM Telecom International社が主導するコンソーシアム(注1)に引き渡ししています。JGAは、グアムで他ケーブルに接続され、日本・オーストラリアと米国・アジア間の通信需要の増加への対応、ネットワークの冗長性の確保、信頼性の高い通信の実現に貢献します。
また、本ケーブルの建設・運用には、株式会社 海外通信・放送・郵便事業支援機構(JICT)の出融資や、NECキャピタルソリューション株式会社を含む日本企業からのシンジケートローンが活用されています。
NECは、過去50年以上にわたり海底ケーブルシステム事業を手掛ける海底ケーブルのトップベンダーです。地球7.5周分のべ30万kmを超える敷設実績があり、特に日本を含むアジア・太平洋地域で強みを有しています。また、陸上に設置する光伝送端局装置・光海底中継器・光海底ケーブルなどの製造、海洋調査とルート設計、光海底ケーブルシステムの据付・敷設工事、訓練から引渡試験まで、全てをシステムインテグレータとして提供しています。なお、日本で唯一、深海8,000メートルの水圧に耐えられる光海底ケーブルを製造可能なNECの子会社である株式会社OCC(注2)が、本ケーブルの製造を担当しています。
本リリースの詳細は下記をご参照ください。
https://jpn.nec.com/press/202007/20200706_03.html
概要：日本電気株式会社（NEC)
詳細は www.nec.co.jp をご覧ください。
Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02
Honda、「N-BOX」シリーズが2020年上半期 新車販売台数 第1位を獲得
N-BOXは、軽乗用車最大級※4の室内空間や存在感のあるデザインに加え、全タイプに標準装備※5とした先進の安全運転支援システム「Honda SENSING（ホンダ センシング）」や、優れた走行性能・燃費性能などで多くのお客様よりご好評をいただいています。
本リリースの詳細は下記をご参照ください。
https://www.honda.co.jp/news/2020/4200706.html
概要：本田技研工業株式会社
詳細は www.honda.co.jp をご覧ください。
Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02
Honda、インドのパワープロダクツ現地法人の社名変更について
Hondaのインドにおけるパワープロダクツ生産販売現地法人が、このほどインド政府より社名変更認可を受けたことにより、社名をホンダ シエル パワープロダクツ リミテッドからホンダ インディア パワープロダクツ リミテッドに変更しました。
Hondaは、2020年3月末日をもってパートナー企業であるウシャ インターナショナル リミテッドとのジョイントベンチャー契約が満了したことに伴い、社名変更に関する認可をインド政府へ申請していましたが、このほど認可の取得に至ったことから、社名変更となりました。Hondaは今後もインドにおける事業を通じてお客様の喜びを拡大していきます。
本リリースの詳細は下記をご参照ください。
https://www.honda.co.jp/news/2020/c200706.html
概要：本田技研工業株式会社
詳細は www.honda.co.jp をご覧ください。
Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02
トヨタ、2000GTの補給部品を復刻・再販売
当プロジェクトは、「思い出の詰まった愛車に乗り続けたい」というお客様の想いに応えるべく、既に廃版となってしまった補給部品を復刻し、純正部品として再販売する取り組みです。既に2019年5月のGRスープラ記者発表会にてA70スープラ、A80スープラの部品復刻・再販売を発表しており、トヨタ 2000GTはそれに続く車種となります。
トヨタ 2000GTはヤマハ発動機(株)の協力を得てトヨタ自動車が1967年に発売したスポーツカーで、1970年の生産終了まで337台が生産されました。直列6気筒DOHC 2,000ccエンジンや4輪ダブルウィッシュボーンサスペンション、4輪ディスクブレーキ、ラジアルタイヤ、マグネシウムホイール、リトラクタブルヘッドランプなど、日本初の技術を採用し、当時の欧州のスポーツカーに並ぶ性能（最高速度220km/h）を誇りました。そして、発売前にはスピードトライアルに挑戦し、台風が近づく悪条件にも関わらず、3つの世界記録（10,000マイル、15,000km、72時間）と13の国際記録も樹立し、さらには様々なレースでも優勝を含め、上位の成績を収めました。また、当時日本を舞台に撮影された映画007シリーズ「007は二度死ぬ」のボンドカーにも採用されるなど、トヨタが世界に誇るスポーツカーでした。
今回発売の品目につきましては、部品復刻に特別にご協力いただいた仕入先様および、社内の工場、関係部署にて製造に向けた準備を進めております。本年8月1日より、準備が整った部品から詳細情報を順次TGR Webサイト※1にて公開、オーダー受付を開始いたします。なお、復刻部品は通常の純正部品と同様に、トヨタの販売店で購入いただけます。但し、トヨタ 2000GTは車両の希少性、部品の転売を防止する観点から、車両のオーナー様のみ、かつ車両当たり数量制限付きでの販売となります。
また、本年1月に公開したA70スープラ、A80スープラの第1弾復刻品目※3の一部（A70フューエルセンダーゲージ、A70ドアハンドル、A80ドアハンドル）も7月1日より国内、海外のトヨタ販売店にてオーダー受付開始となっています。他の品目のオーダー受付開始時期はTGR Webサイトにて公開しています。
本リリースの詳細は下記URLをご参照ください。
https://global.toyota/jp/newsroom/toyota/33072948.html
概要：トヨタ自動車株式会社
詳細は http://toyota.jp/ をご覧ください。
Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02
HOYAと日立、超音波内視鏡システムの長期技術提携および製品供給に合意
日立の画像診断関連事業は、国内外の競争法その他の法令等に基づき必要なクリアランス・許認可等の取得が完了することを条件として、富士フイルム株式会社(以下、富士フイルム)へ譲渡される予定であり、本合意は富士フイルムへ譲渡された後も継続されます。
HOYA株式会社 PENTAX Medical グローバル事業部長 ジェラルドW.ボッテロは次のように述べています。「日立との提携は1983年の共同研究開始にさかのぼり、1990年にEUSシステムを発売しました。日立の超音波診断装置は、EUSにおいて世界的に認められている性能を有し、優れた画質、先進的なソフトウェア、使いやすさに定評があります。技術提携と製品供給が継続されることは大変名誉なことで、今後も引き続き日立が誇る世界トップクラスの開発チームと共に、EUSにおける技術革新と実用化の推進に取り組んでまいります。」
株式会社日立製作所 ヘルスケアビジネスユニット CTO 河野敏彦は次のように述べています。「HOYA株式会社 PENTAX Medicalとの超音波内視鏡に関する協業を今後も継続することができて非常に喜ばしく思います。日立とPENTAX Medicalは30年以上にわたり、一緒になって超音波内視鏡の革新的な技術を開発してきました。我々はこれからもこの協業を継続していき、超音波内視鏡検査において、より優れた診断と治療につながる新しい臨床価値を提供していきます。」
HOYAについて
1941年創業、ヘルスケアや医療関連製品を扱う「ライフケア」と、情報化社会を支える精密部材などを扱う「情報通信」の2つの事業分野を展開しています。ライフケア分野では、メガネレンズ、コンタクトレンズおよび眼内レンズ、内視鏡や人口骨、外科処置や洗浄を行う各種医療機器を展開しています。情報通信分野では、半導体およびLCD/OLEDパネルの製造工程で使用されるフォトマスクやブランクス、クラウドストレージにおいて重要なHDD向けのガラス基板、カメラ用の光学レンズ、音声合成や各種ソフトウェアを展開しています。現在、世界150か所以上の拠点において、多様な国籍の従業員が37,000人以上在籍しています。
日立製作所について
日立は、IT(Information Technology)、OT(Operational Technology)およびプロダクトを組み合わせた社会イノベーション事業に注力しています。2019年度の連結売上収益は8兆7,672億円、2020年3月末時点の連結従業員数は約301,000人でした。日立は、モビリティ、ライフ、インダストリー、エネルギー、ITの5分野でLumadaを活用したデジタルソリューションを提供することにより、お客さまの社会価値、環境価値、経済価値の3つの価値向上に貢献します。
本リリースの詳細は下記URLをご参照ください。
https://www.hitachi.co.jp/New/cnews/month/2020/07/0706.html
概要：日立製作所
詳細は www.hitachi.co.jp をご参照ください。
Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02
7/5/20
Favored by Capital Market Again, MicroPort's CRM Business Brings in New Investor
HONG KONG, Jul 6, 2020 - (JCN Newswire) - Thanks to capital market's growing expectation for the aging population and accelerated substitution of imported medical devices, China's medical devices industry has entered a golden age of rapid development. Hong Kong-listed medical devices company, MicroPort Scientific Corporation ("MicroPort",stock code: 00853) - which has positioned in ten business segments including cardiovascular devices, orthopedics devices, and cardiac rhythm management business - was favored by the capital market in 2020 and obtained substantial attention from a lot of heavyweight strategic investors.
Following its announcement on July 2 in relation to completion of the placing of 65,958,000 new shares and raising over HK$1.5 billion at a price with the lowest discount among all primary placings of healthcare companies listed in Hong Kong in the last 5 years, MicroPort announced on 5 July that its subsidiary - MicroPort Cardiac Rhythm Management Limited ("MicroPort CRM"), which focuses on developing and commercializing implantable pacemaker and defibrillator devices and related technologies to manage cardiac rhythm disorders - has entered into definitive agreements in connection with its Series B financing with total investment proceeds US$105 million. With the investments, MicroPort CRM's post-money valuation reaches about US$400 million. Hillhouse Capital Group will lead the Series B investment and will invest US$50 million. Current MicroPort CRM investor, Yunfeng Capital will also participate with an additional investment of US$25 million. MicroPort will also invest USD$30 million through its wholly owned subsidiary. These investments fully demonstrated investors' confidence on the development of medical devices industry and MicroPort CRM business.
Originally acquired in April 2018, MicroPort CRM designs, develops, and markets solutions for the management of heart rhythm disorders, such as implantable pacemakers and defibrillators, as well as heart failure with cardiac resynchronization therapy (CRT), worldwide. Headquartered in Clamart (outside Paris) France, MicroPort CRM has dedicated R&D teams in Clamart (outside Paris) and Shanghai, and world class manufacturing facilities in France, Italy, the Dominican Republic and China. Currently MicroPort CRM employs approximately 950 employees globally.
For decades, MicroPort CRM has been at the forefront of innovation in the CRM industry and has implanted more than one million patients worldwide with its pacemakers and defibrillators. The company is known for its cutting-edge technology, small, long-lasting devices, and the most advanced therapeutic solutions. In 2015, MicroPort CRM launched the PLATINIUMTM family of implantable defibrillators, which has the longest service life of any implantable defibrillator on the market, reducing the risks associated to frequent replacements. In 2019, the company launched ENOTM, TEOTM and OTOTM, the world's smallest family of pacemakers, 1.5T and 3T MRI conditional. In the CRT field, the company innovated with the SonRTM sensor, the world's only contractility sensor for automatic optimization of cardiac resynchronization, which, in a landmark trial called RESPOND-CRT, revealed that SonRTM is associated with a 35% reduction in the risk of hospitalization for heart failure. MicroPort CRM continues to innovate in CRT by developing AXONETM, an ultra-thin 1.2 F (0.4 mm) left ventricular lead, which will enable MicroPort CRM to lead the industry in expanding CRT therapy options.
MicroPort CRM will soon launch a new family of pacemakers, ALIZEATM and BOREATM, featuring Bluetooth technology and wireless remote monitoring, and plans to launch a complete new line of defibrillator systems in 2021, including devices and leads, 1.5T and 3T MRI conditional. The market introduction of these products will provide an additional inflection point for the growth prospects of the CRM franchise.
Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02
Following its announcement on July 2 in relation to completion of the placing of 65,958,000 new shares and raising over HK$1.5 billion at a price with the lowest discount among all primary placings of healthcare companies listed in Hong Kong in the last 5 years, MicroPort announced on 5 July that its subsidiary - MicroPort Cardiac Rhythm Management Limited ("MicroPort CRM"), which focuses on developing and commercializing implantable pacemaker and defibrillator devices and related technologies to manage cardiac rhythm disorders - has entered into definitive agreements in connection with its Series B financing with total investment proceeds US$105 million. With the investments, MicroPort CRM's post-money valuation reaches about US$400 million. Hillhouse Capital Group will lead the Series B investment and will invest US$50 million. Current MicroPort CRM investor, Yunfeng Capital will also participate with an additional investment of US$25 million. MicroPort will also invest USD$30 million through its wholly owned subsidiary. These investments fully demonstrated investors' confidence on the development of medical devices industry and MicroPort CRM business.
Originally acquired in April 2018, MicroPort CRM designs, develops, and markets solutions for the management of heart rhythm disorders, such as implantable pacemakers and defibrillators, as well as heart failure with cardiac resynchronization therapy (CRT), worldwide. Headquartered in Clamart (outside Paris) France, MicroPort CRM has dedicated R&D teams in Clamart (outside Paris) and Shanghai, and world class manufacturing facilities in France, Italy, the Dominican Republic and China. Currently MicroPort CRM employs approximately 950 employees globally.
For decades, MicroPort CRM has been at the forefront of innovation in the CRM industry and has implanted more than one million patients worldwide with its pacemakers and defibrillators. The company is known for its cutting-edge technology, small, long-lasting devices, and the most advanced therapeutic solutions. In 2015, MicroPort CRM launched the PLATINIUMTM family of implantable defibrillators, which has the longest service life of any implantable defibrillator on the market, reducing the risks associated to frequent replacements. In 2019, the company launched ENOTM, TEOTM and OTOTM, the world's smallest family of pacemakers, 1.5T and 3T MRI conditional. In the CRT field, the company innovated with the SonRTM sensor, the world's only contractility sensor for automatic optimization of cardiac resynchronization, which, in a landmark trial called RESPOND-CRT, revealed that SonRTM is associated with a 35% reduction in the risk of hospitalization for heart failure. MicroPort CRM continues to innovate in CRT by developing AXONETM, an ultra-thin 1.2 F (0.4 mm) left ventricular lead, which will enable MicroPort CRM to lead the industry in expanding CRT therapy options.
MicroPort CRM will soon launch a new family of pacemakers, ALIZEATM and BOREATM, featuring Bluetooth technology and wireless remote monitoring, and plans to launch a complete new line of defibrillator systems in 2021, including devices and leads, 1.5T and 3T MRI conditional. The market introduction of these products will provide an additional inflection point for the growth prospects of the CRM franchise.
Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02
Favored by Capital Market Again, MicroPort's CRM Business Brings in New Investor
HONG KONG, Jul 6, 2020 - (ACN Newswire) - Thanks to capital market's growing expectation for the aging population and accelerated substitution of imported medical devices, China's medical devices industry has entered a golden age of rapid development. Hong Kong-listed medical devices company, MicroPort Scientific Corporation ("MicroPort",stock code: 00853) - which has positioned in ten business segments including cardiovascular devices, orthopedics devices, and cardiac rhythm management business - was favored by the capital market in 2020 and obtained substantial attention from a lot of heavyweight strategic investors.
Following its announcement on July 2 in relation to completion of the placing of 65,958,000 new shares and raising over HK$1.5 billion at a price with the lowest discount among all primary placings of healthcare companies listed in Hong Kong in the last 5 years, MicroPort announced on 5 July that its subsidiary - MicroPort Cardiac Rhythm Management Limited ("MicroPort CRM"), which focuses on developing and commercializing implantable pacemaker and defibrillator devices and related technologies to manage cardiac rhythm disorders - has entered into definitive agreements in connection with its Series B financing with total investment proceeds US$105 million. With the investments, MicroPort CRM's post-money valuation reaches about US$400 million. Hillhouse Capital Group will lead the Series B investment and will invest US$50 million. Current MicroPort CRM investor, Yunfeng Capital will also participate with an additional investment of US$25 million. MicroPort will also invest USD$30 million through its wholly owned subsidiary. These investments fully demonstrated investors' confidence on the development of medical devices industry and MicroPort CRM business.
Originally acquired in April 2018, MicroPort CRM designs, develops, and markets solutions for the management of heart rhythm disorders, such as implantable pacemakers and defibrillators, as well as heart failure with cardiac resynchronization therapy (CRT), worldwide. Headquartered in Clamart (outside Paris) France, MicroPort CRM has dedicated R&D teams in Clamart (outside Paris) and Shanghai, and world class manufacturing facilities in France, Italy, the Dominican Republic and China. Currently MicroPort CRM employs approximately 950 employees globally.
For decades, MicroPort CRM has been at the forefront of innovation in the CRM industry and has implanted more than one million patients worldwide with its pacemakers and defibrillators. The company is known for its cutting-edge technology, small, long-lasting devices, and the most advanced therapeutic solutions. In 2015, MicroPort CRM launched the PLATINIUMTM family of implantable defibrillators, which has the longest service life of any implantable defibrillator on the market, reducing the risks associated to frequent replacements. In 2019, the company launched ENOTM, TEOTM and OTOTM, the world's smallest family of pacemakers, 1.5T and 3T MRI conditional. In the CRT field, the company innovated with the SonRTM sensor, the world's only contractility sensor for automatic optimization of cardiac resynchronization, which, in a landmark trial called RESPOND-CRT, revealed that SonRTM is associated with a 35% reduction in the risk of hospitalization for heart failure. MicroPort CRM continues to innovate in CRT by developing AXONETM, an ultra-thin 1.2 F (0.4 mm) left ventricular lead, which will enable MicroPort CRM to lead the industry in expanding CRT therapy options.
MicroPort CRM will soon launch a new family of pacemakers, ALIZEATM and BOREATM, featuring Bluetooth technology and wireless remote monitoring, and plans to launch a complete new line of defibrillator systems in 2021, including devices and leads, 1.5T and 3T MRI conditional. The market introduction of these products will provide an additional inflection point for the growth prospects of the CRM franchise.
Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com
source http://www.acnnewswire.com/press-release/english/60032/
Following its announcement on July 2 in relation to completion of the placing of 65,958,000 new shares and raising over HK$1.5 billion at a price with the lowest discount among all primary placings of healthcare companies listed in Hong Kong in the last 5 years, MicroPort announced on 5 July that its subsidiary - MicroPort Cardiac Rhythm Management Limited ("MicroPort CRM"), which focuses on developing and commercializing implantable pacemaker and defibrillator devices and related technologies to manage cardiac rhythm disorders - has entered into definitive agreements in connection with its Series B financing with total investment proceeds US$105 million. With the investments, MicroPort CRM's post-money valuation reaches about US$400 million. Hillhouse Capital Group will lead the Series B investment and will invest US$50 million. Current MicroPort CRM investor, Yunfeng Capital will also participate with an additional investment of US$25 million. MicroPort will also invest USD$30 million through its wholly owned subsidiary. These investments fully demonstrated investors' confidence on the development of medical devices industry and MicroPort CRM business.
Originally acquired in April 2018, MicroPort CRM designs, develops, and markets solutions for the management of heart rhythm disorders, such as implantable pacemakers and defibrillators, as well as heart failure with cardiac resynchronization therapy (CRT), worldwide. Headquartered in Clamart (outside Paris) France, MicroPort CRM has dedicated R&D teams in Clamart (outside Paris) and Shanghai, and world class manufacturing facilities in France, Italy, the Dominican Republic and China. Currently MicroPort CRM employs approximately 950 employees globally.
For decades, MicroPort CRM has been at the forefront of innovation in the CRM industry and has implanted more than one million patients worldwide with its pacemakers and defibrillators. The company is known for its cutting-edge technology, small, long-lasting devices, and the most advanced therapeutic solutions. In 2015, MicroPort CRM launched the PLATINIUMTM family of implantable defibrillators, which has the longest service life of any implantable defibrillator on the market, reducing the risks associated to frequent replacements. In 2019, the company launched ENOTM, TEOTM and OTOTM, the world's smallest family of pacemakers, 1.5T and 3T MRI conditional. In the CRT field, the company innovated with the SonRTM sensor, the world's only contractility sensor for automatic optimization of cardiac resynchronization, which, in a landmark trial called RESPOND-CRT, revealed that SonRTM is associated with a 35% reduction in the risk of hospitalization for heart failure. MicroPort CRM continues to innovate in CRT by developing AXONETM, an ultra-thin 1.2 F (0.4 mm) left ventricular lead, which will enable MicroPort CRM to lead the industry in expanding CRT therapy options.
MicroPort CRM will soon launch a new family of pacemakers, ALIZEATM and BOREATM, featuring Bluetooth technology and wireless remote monitoring, and plans to launch a complete new line of defibrillator systems in 2021, including devices and leads, 1.5T and 3T MRI conditional. The market introduction of these products will provide an additional inflection point for the growth prospects of the CRM franchise.
Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com
source http://www.acnnewswire.com/press-release/english/60032/
VIET CAPITAL BANK and 7-ELEVEN VIETNAM Launch JCB CARD
 |
|
|
A great population of more than 90 million people, Vietnam is considered an attractive market for consumer goods. Vietnamese people likely change the habit in purchasing consumer goods, need to be convinced and purchase all the time 24/7. That's causing the rapidly opening of convenience store.
7-Eleven Vietnam is evaluated as a reputation convenience store, in which developing utilities especially in diversifying the payment, and increasing the loyalty of customer, the co-branded card is launched.
As Viet Capital Bank and 7-Eleven Vietnam exploring,
- 7-Eleven Vietnam expect to operate 1000 stores by 2027.
- This is the first co-branded card of convenience store in Viet Nam.
- With the first step of the campaign, Viet Capital Bank and 7-Eleven Vietnam will prioritize and specifically focus on those group customers are currently member of 7-Eleven Vietnam.
The cardholders can access the JCB acceptance network with about 34 million merchants around the world, special privileges at selected merchants, and customer service at JCB Plaza, an overseas service counter.
In addition, Viet Capital Bank and 7-Eleven offers a lot of benefits with cardholders.
1) Free lifetime annual fee for cardholder, grace period up to 55 days.
2) Loyalty program from 7-Eleven: 1 point for each 1,000 VND transaction amount in App 7REWARDS.
3) Loyalty program from Viet Capital Bank: 5 point for each 1,000 VND transaction amount.
About Viet Capital Bank
Viet Capital Commercial Joint Stock Bank was established in 1992. Over 27 years of operation, with many changes, up to now with the right business vision and strategy, Ban Viet Bank is gradually asserting its position on financial and banking market with the ability to flexibly meet the diverse needs of customers' products and services. The Bank has planned and implemented the Development Strategy for the period of 2016-2020 with the message "We started from YOU" to aim to become a modern, versatile, customer-oriented retail bank. especially individual customers and small and medium business customers.
About 7-Eleven Viet Nam
The first 7-Eleven store in Viet Nam opens in 2017, making Viet Nam the 19th country to host the world's largest convenience store chain.
Seven System Viet Nam (SSV) is the Master Franchisee of the 7-Eleven convenience store system in Viet Nam, based in Ho Chi Minh City. SSV is a group of dynamic professionals who relentlessly make great efforts every day to continue the success story of this iconic brand.
Our mission is to always put our customers first - bringing them fresh food, convenient products and essential services compatible with the culture and lifestyle of a modern and dynamic Viet Nam.
About JCB
JCB is a global payment brand and a leading credit card issuer and acquirer in Japan. JCB launched its card business in Japan in 1961 and began expanding worldwide in 1981. Its acceptance network includes about 34 million merchants as well as cash advance locations around the world. As a comprehensive payment solution provider, JCB commits to providing responsive and high-quality service and products to all customers worldwide. For more information, please visit: www.global.jcb/en/
Contact
JCB Co., Ltd.
Kumiko Kida, Ayaka Nakajima
Corporate Communications Department
Tel: +81-3-5778-8353
E-Mail: jcb-pr@jcb.co.jp
Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com
source http://www.acnnewswire.com/press-release/english/60020/
エーザイ、抗てんかん剤「フィコンパ(R)」（一般名：ペランパネル水和物）の新剤形となる細粒剤を新発売
日本におけるてんかん患者様数は約 100 万人と推定されています。てんかんは、年齢に関係なく発症する疾患ですが、特に小児と高齢者で発症率が高いといわれています。新発売の細粒剤は、小児や嚥下機能の低下によって錠剤の服用が困難な患者様にも服用いただける剤形として開発されました。また、患者様の症状に合わせた用量調節も可能となります。
「フィコンパ」は、当社筑波研究所で創製されたファースト・イン・クラスの抗てんかん剤です。本剤は、グルタミン酸によるシナプス後膜の AMPA 受容体を選択的かつ非競合的に阻害し、神経の過興奮を抑制します。本剤は日本において、4 歳以上のてんかん患者様の部分発作（二次性全般化発作を含む）に対する単剤および併用療法、また 12 歳以上のてんかん患者様の強直間代発作に対する併用療法の承認を取得しています。
当社は、今回の「フィコンパ」の細粒剤に係る新発売を機に、引き続き、安全性情報提供を最優先とした活動を行い、より多くの患者様に発作フリー（seizure freedom）をお届けする使命を追求し、てんかん患者様とそのご家族の多様なニーズの充足とベネフィット向上により一層貢献してまいります。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2020/news202035.html
概要：エーザイ株式会社
詳細は www.eisai.co.jp をご覧ください。
Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02
富士通、ニューノーマルにおける新たな働き方「Work Life Shift」を推進
「Work Life Shift」は、「働く」ということだけでなく、「仕事」と「生活」をトータルにシフトし、Well-beingを実現するコンセプトです。このコンセプトのもと、固定的なオフィスに出勤する従来の通勤の概念を変え、多様な人材が高い自律性と相互の信頼に基づき、場所や時間にとらわれることなくお客様への提供価値の創造と自らの変革に継続的に取り組むことができる働き方を実現するため、人事制度とオフィス環境整備の両面から様々な施策を推進します。オフィス環境面では、従業員がそれぞれの業務目的に最も適した場所から自由に選択できるようにするとともに、全席をフリーアドレス化することにより、2022年度末までにオフィスの規模を現状の50％程度に最適化（注1）し、快適で創造性のあるオフィス環境を構築します。
当社は今後も、「パーパス」（注2）の実現に向けた最適な働き方を追求していくとともに、社内実践した新たな働き方をお客様にリファレンスとして提供することで、お客様のDXの実現にも貢献していきます。
本リリースの詳細は下記をご参照ください。
https://pr.fujitsu.com/jp/news/2020/07/6.html
概要：富士通株式会社
詳細は http://jp.fujitsu.com/ をご覧ください。
Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02
エーザイ、自社創製の新規不眠症治療薬「デエビゴ(R)」（一般名：レンボレキサント）が日本において不眠症に対する適応で新発売
「デエビゴ」は、脳内で覚醒に関与するオレキシン受容体の 2 種のサブタイプ（オレキシン 1 および 2受容体）に対し、オレキシンと競合的に結合する拮抗剤です。本剤は、覚醒を制御しているオレキシン神経伝達に作用し、睡眠覚醒リズムを整えることで、入眠と睡眠維持および覚醒を調整すると考えられています。
日本における「デエビゴ」の承認は、不眠症の成人患者様を対象に実施した 2 つのピボタル臨床第III相試験１,2（SUNRISE1 試験および SUNRISE2 試験）、および夜間覚醒時および翌日の姿勢安定性（ふらつき、転倒リスクの予測因子）や記憶力などの持ち越し効果について評価した安全性試験（106試験 3、108 試験 4）の結果に基づくものです。
北米と欧州において実施した SUNRISE1 試験において、主要評価項目である睡眠潜時、副次評価項目である睡眠効率、中途覚醒時間について、睡眠ポリグラフによる終夜測定を用いて客観的に評価した結果、「デエビゴ」投与群は、ゾルピデム酒石酸塩徐放性製剤（6.25mg、国内未承認）投与群およびプラセボ投与群に対して、統計学的に有意な短縮および改善が確認されました。日本を含むグローバルに実施した SUNRISE2 試験において、主要評価項目である睡眠潜時、ならびに副次評価項目である睡眠効率および中途覚醒時間について、患者様の睡眠日誌を用いて主観評価を行った結果、「デエビゴ」投与群は、プラセボ投与群に対して、統計学的に有意な改善が確認されました。両試験で本剤について観察された主な副作用は、傾眠、頭痛、浮動性めまい、疲労でした。両試験において、本剤の投与中止により投与前よりも強い不眠症状が現れる反跳性不眠、および投与中止後の離脱症状は観察されず、最長1年間投与している患者様においても、身体的依存を引き起こさないことが示唆されました。
安全性として、「デエビゴ」（5mg、10mg）投与による健康成人または高齢者の翌朝の自動車運転能力への影響が評価され（106 試験 3）、いずれの用量においても「デエビゴ」投与群はプラセボ投与群と比較して統計学的に有意な低下は確認されませんでした。さらに夜間覚醒時および翌日の姿勢安定性（ふらつき、転倒リスクの予測因子）や記憶力などの持ち越し効果についても評価され（108 試験 4）、「デエビゴ」投与群は、夜間覚醒時に姿勢が不安定になる可能性や、注意力低下および記憶障害に注意する必要がある一方、翌日のふらつきおよび記憶力についてプラセボ投与群と比較して問題となるような悪化は見られませんでした。
本剤は、入眠困難、睡眠維持困難のいずれかまたはその両方を伴う成人の不眠症の適応で、2020年 6 月に米国において新発売しました。また、カナダ、オーストラリアにおいては新薬承認申請中です。
不眠症は、睡眠をとる十分な機会があるにもかかわらず、入眠困難、睡眠維持困難のいずれかまたはその両方の症状を持つことが特徴です。全世界で成人の約 30％の方が不眠症の症状を有する 7、8、罹患頻度の高い睡眠障害のひとつです。特に高齢者の有病率は高い傾向にあり、多くの場合、その症状は長期にわたります。不眠症は、疲労、集中困難、易刺激性により 5、6、長期欠勤や生産性の低下などの社会的損失を引き起こし、高齢者においてはふらつきの原因となり転倒のリスクとなっています 9。
当社は、「デエビゴ」の販売を通じ、不眠症治療薬の適正使用、安全性情報提供を最優先とした活動を行ってまいります。また、不眠症の患者様に新たな治療選択肢「デエビゴ」をお届けすることにより、速やかな入眠と良質な睡眠維持によってもたらされる日中の活力ある生活の実現と、患者様のリワーク/リカバリーに貢献してまいります。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2020/news202036.html
概要：エーザイ株式会社
詳細は www.eisai.co.jp をご覧ください。
Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02
Privity FZ LLE participates in Verofax pre-seed investment round
DUBAI, UAE, Jul 5, 2020 - (JCN Newswire) - Verofax Limited, a start-up building innovative Traceability services with the application of blockchain, closed its recent pre-seed investment round with participation from Privity FZ LLE, based in the UAE, acquiring an equity stake. Privity is an independent venture-focused advisory firm, founded in Dubai in 2004, that has backed and invested in more than a dozen portfolio companies since its inception.
Wassim Merheby, Verofax CEO, commented, "We are truly thrilled to welcome Privity as a shareholder in Verofax. Traceability plays a key role in upgrading brand owners' business through authenticity validation, advanced product marketing and access to financing and global markets. Traceability is a key enabler of digital transformation to automated and resilient supply chain services. In the markets where Traceability has been deployed such as China, sales increased by over 30% while consumer complaints dropped by 42%. It is just a matter of time for Traceability to become a must for ShopSafe compliance regulations, currently under review in the US."
Mr. Merheby is leading transformation projects for the Health authorities in UAE in relation to eHealth native digital services, and promoting patient safety through the application of integrated technologies. The world has just been hit by a pandemic which clearly points out that Healthcare could be better managed with contactless processes applying technologies such as IOT devices, drones, blockchain, AI, and augmented reality. The most immediate need is for the safe delivery of eHealth services, where Verofax offers wide applicability for the underlying systems of the Healthcare and supply chain industries.
Sleem Hasan, Privity Founder and CEO, said "Privity participated alongside reputed regional investors in the pre-seed round of investment in Verofax. This is also Privity's first portfolio company based in the UAE, and its second HealthTech venture. I am delighted to open Privity's network to Verofax as I find the underlying value proposition of their business idea compelling. COVID-19 has demonstrated the need to transform secure delivery and offer protection to the most vulnerable in our society. Verofax services are perfectly positioned and aligned to secure pharmaceutical deliveries of medication in the region with privacy and safety."
Verofax proprietary traceability and delivery solutions powers unique compliance and brand protection services, including serialization, traceability, anti-counterfeit and anti-diversion solutions. The service supports manufacturers of food, pharmaceuticals and other consumer goods, in meeting evolving product traceability regulations and growing consumer demand for product safety, security and authenticity.
About Verofax
Verofax Limited is a blockchain-enabled, traceability service provider established in Abu Dhabi Global Markets, UAE. Verofax services have been accepted by Oracle, Microsoft and Ant Group for co-selling across their established B2B channels. Verofax has recently set up subsidiary entities in Malaysia and Estonia, to offer Traceability-as-a-service across wider geographies.
About Privity
Privity FZ LLE was founded in 2004, an independent venture-focused advisory firm that seeks entrepreneurs with interesting and unique ideas and helps them develop and grow. Privity is agnostic to geography and industry vertical. It focuses on the quality of the entrepreneur and the compelling value proposition of the idea.
Visit Verofax at https://verofax.com, and Privity FZ LLE at http://www.privitylle.com.
Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02
Wassim Merheby, Verofax CEO, commented, "We are truly thrilled to welcome Privity as a shareholder in Verofax. Traceability plays a key role in upgrading brand owners' business through authenticity validation, advanced product marketing and access to financing and global markets. Traceability is a key enabler of digital transformation to automated and resilient supply chain services. In the markets where Traceability has been deployed such as China, sales increased by over 30% while consumer complaints dropped by 42%. It is just a matter of time for Traceability to become a must for ShopSafe compliance regulations, currently under review in the US."
Mr. Merheby is leading transformation projects for the Health authorities in UAE in relation to eHealth native digital services, and promoting patient safety through the application of integrated technologies. The world has just been hit by a pandemic which clearly points out that Healthcare could be better managed with contactless processes applying technologies such as IOT devices, drones, blockchain, AI, and augmented reality. The most immediate need is for the safe delivery of eHealth services, where Verofax offers wide applicability for the underlying systems of the Healthcare and supply chain industries.
Sleem Hasan, Privity Founder and CEO, said "Privity participated alongside reputed regional investors in the pre-seed round of investment in Verofax. This is also Privity's first portfolio company based in the UAE, and its second HealthTech venture. I am delighted to open Privity's network to Verofax as I find the underlying value proposition of their business idea compelling. COVID-19 has demonstrated the need to transform secure delivery and offer protection to the most vulnerable in our society. Verofax services are perfectly positioned and aligned to secure pharmaceutical deliveries of medication in the region with privacy and safety."
Verofax proprietary traceability and delivery solutions powers unique compliance and brand protection services, including serialization, traceability, anti-counterfeit and anti-diversion solutions. The service supports manufacturers of food, pharmaceuticals and other consumer goods, in meeting evolving product traceability regulations and growing consumer demand for product safety, security and authenticity.
About Verofax
Verofax Limited is a blockchain-enabled, traceability service provider established in Abu Dhabi Global Markets, UAE. Verofax services have been accepted by Oracle, Microsoft and Ant Group for co-selling across their established B2B channels. Verofax has recently set up subsidiary entities in Malaysia and Estonia, to offer Traceability-as-a-service across wider geographies.
About Privity
Privity FZ LLE was founded in 2004, an independent venture-focused advisory firm that seeks entrepreneurs with interesting and unique ideas and helps them develop and grow. Privity is agnostic to geography and industry vertical. It focuses on the quality of the entrepreneur and the compelling value proposition of the idea.
Visit Verofax at https://verofax.com, and Privity FZ LLE at http://www.privitylle.com.
Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02
Privity FZ LLE participates in Verofax pre-seed investment round
Wassim Merheby, Verofax CEO, commented, "We are truly thrilled to welcome Privity as a shareholder in Verofax. Traceability plays a key role in upgrading brand owners' business through authenticity validation, advanced product marketing and access to financing and global markets. Traceability is a key enabler of digital transformation to automated and resilient supply chain services. In the markets where Traceability has been deployed such as China, sales increased by over 30% while consumer complaints dropped by 42%. It is just a matter of time for Traceability to become a must for ShopSafe compliance regulations, currently under review in the US."
Mr. Merheby is leading transformation projects for the Health authorities in UAE in relation to eHealth native digital services, and promoting patient safety through the application of integrated technologies. The world has just been hit by a pandemic which clearly points out that Healthcare could be better managed with contactless processes applying technologies such as IOT devices, drones, blockchain, AI, and augmented reality. The most immediate need is for the safe delivery of eHealth services, where Verofax offers wide applicability for the underlying systems of the Healthcare and supply chain industries.
Sleem Hasan, Privity Founder and CEO, said "Privity participated alongside reputed regional investors in the pre-seed round of investment in Verofax. This is also Privity's first portfolio company based in the UAE, and its second HealthTech venture. I am delighted to open Privity's network to Verofax as I find the underlying value proposition of their business idea compelling. COVID-19 has demonstrated the need to transform secure delivery and offer protection to the most vulnerable in our society. Verofax services are perfectly positioned and aligned to secure pharmaceutical deliveries of medication in the region with privacy and safety."
Verofax proprietary traceability and delivery solutions powers unique compliance and brand protection services, including serialization, traceability, anti-counterfeit and anti-diversion solutions. The service supports manufacturers of food, pharmaceuticals and other consumer goods, in meeting evolving product traceability regulations and growing consumer demand for product safety, security and authenticity.
About Verofax
Verofax Limited is a blockchain-enabled, traceability service provider established in Abu Dhabi Global Markets, UAE. Verofax services have been accepted by Oracle, Microsoft and Ant Group for co-selling across their established B2B channels. Verofax has recently set up subsidiary entities in Malaysia and Estonia, to offer Traceability-as-a-service across wider geographies.
About Privity
Privity FZ LLE was founded in 2004, an independent venture-focused advisory firm that seeks entrepreneurs with interesting and unique ideas and helps them develop and grow. Privity is agnostic to geography and industry vertical. It focuses on the quality of the entrepreneur and the compelling value proposition of the idea.
Visit Verofax at https://verofax.com, and Privity FZ LLE at http://www.privitylle.com.
Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com
source http://www.acnnewswire.com/press-release/english/60019/
7/3/20
先見の明のない製品StickSafeは、前例のないウイルスの蔓延との戦いにおいて、その正当な位置をついに見つけました
数年前にクリストファー・アビナに登場したアイデアは、元々ぬるい歓迎を受けましたが、今では目に見えない敵の拡散を阻止するのに役立つ可能性があります。
コロラド州デンバーから車でわずか30分で、若いAvinaが数年前にStickSafeを作成しました。このハイテクステッカーは、抗ウイルス性と抗菌性のあるハイテク素材で作られており、私たちがよく触れるあらゆる物体や表面に貼り付けることができます。
Lukewarmレセプション
当時、若いアヴィーナは彼の発見に非常に興奮していました。彼がそれが命を救う可能性があることを知っていたからです。彼は資金調達を模索しましたが、潜在的な投資家が彼の発明にぬるぬるレセプションを与えたことに驚きました。
製品の有用性は明らかでしたが、どこに適用できるか、どのように販売できるかはわかりませんでした。 Avinaは、彼と取引する場合、製品に大幅な変更を要求することもあったことを覚えています。彼の発明をしっかりと信じて、彼はどんな取引からも離れて歩く方が良いだろうと決めました。
反発の台頭
現在米国で確認されているCOVID-19の発生率は240万人で、すでに124,000人の死者が記録されているため、予測は悲惨であり、死者数は20万人に達すると考えられています。厳しい制限があっても、ウイルスは急増しており、完全なロックダウンを永久に実装することは現実的ではありません。
企業、学校、オフィスが再開すると、人々が毎日触れる何百もの表面や物体があります。通勤のボタン、エレベーターのボタン、ドアハンドル、コンピューターのキーパッドなど。目に見えない長持ちするウイルスは、これらの表面のどこにでも存在し、他の表面に簡単に移動し、経済を存続させる人々の命を危険にさらします。
StickSafeはバクテリアやウイルスの拡散を防ぐことができますが、その可能性は数年前には評価されていませんでしたが、今では完全に安全な予防策としての希望を提供しています。このコロナウイルスは世界中で大混乱を引き起こし、少なくとも2年間はピークに達し続けると予想されており、科学者はこれが多くの未知のウイルスや細菌の発生が見られる新しい時代の始まりとなる可能性があると警告しています私たちに。
StickSafeで命を救う
ステッカーに使用されている革新的な素材は無毒で安全であるだけでなく、耐久性にも優れています。 StickSaveは無数の表面やオブジェクトに適用でき、通常の作業条件下で最長60日間持続します。誰かがその表面に触れるたびに、ステッカーはすぐに細菌やバクテリアを中和します。これは、世界中の何百万という人々の潜在的な命の恩人です。
StickSafeの用途は無限であり、飛行機やタクシー、空港、駅、スタジアム、ショッピングモール、レストラン、オフィスエリア、学校、家など、あらゆる輸送モードに配置できます。ワンタッチで、命にかかわるあらゆるものを即座に殺し、ウイルスが次の人に広がるのを防ぎます。
2番目の波の防止
予測された第2波の前に、今こそ予防策を講じる良い機会です。StickSafeを使用すると、すべての領域を安全に保つために必要な作業が少なくなります。現在、人々は消毒剤を持って歩き回っており、漂白剤の販売は急上昇していますが、これには多くの労力と時間がかかり、他の場所で使用することができます。
StickSafeのような製品を使用する明らかな利点はたくさんありますが、最も印象的なのは、ウイルスがどのように変異しても、ステッカーは接触時にすぐに殺され、そのたびに変異に対抗する新しいワクチンの作成を待つ必要がないことです。
先の道に資金を提供する
潜んでいるウイルスや細菌の危険に先んじて、StickSafeの生産はすぐに展開する必要があります。これにより、すべての人、特に高齢者と子供たちの保護が確保されます。
生産を迅速に展開するには、StickSafeがすでに予約済みの専用機械を購入するための財政支援が必要です。Christopher Avinaは、完全に米国で製造された高品質の製品の必要性を強調しています。これにより、アメリカ人の雇用を増やすだけでなく、使用する材料の品質や製造プロセスを管理することもできます。
最後に、StickSafeはCOVID-19に取り組むためのソリューションを世界に提供します。私たちが再び人生をスタートさせようとするとき、StickSafeのドリームチームは、StickSafeを将来に向けて設計し続けることで世界中で命を救うすべてのアメリカの製品にするという課題に取り組む決意です。
Main Press contact:
Christopher Avina, CEO
+1 720 648 6094
CEO@sticksafe.us
Website:
https://www.sticksafe.us/about
https://www.indiegogo.com/projects/sticksafe
Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02
先見の明のない製品StickSafeは、前例のないウイルスの蔓延との戦いにおいて、その正当な位置をついに見つけました
TOKYO, Jul 4, 2020 - (JCN Newswire) - 数年前にクリストファー・アビナに登場したアイデアは、元々ぬるい歓迎を受けましたが、今では目に見えない敵の拡散を阻止するのに役立つ可能性があります。
コロラド州デンバーから車でわずか30分で、若いAvinaが数年前にStickSafeを作成しました。このハイテクステッカーは、抗ウイルス性と抗菌性のあるハイテク素材で作られており、私たちがよく触れるあらゆる物体や表面に貼り付けることができます。
Lukewarmレセプション
当時、若いアヴィーナは彼の発見に非常に興奮していました。彼がそれが命を救う可能性があることを知っていたからです。彼は資金調達を模索しましたが、潜在的な投資家が彼の発明にぬるぬるレセプションを与えたことに驚きました。
製品の有用性は明らかでしたが、どこに適用できるか、どのように販売できるかはわかりませんでした。 Avinaは、彼と取引する場合、製品に大幅な変更を要求することもあったことを覚えています。彼の発明をしっかりと信じて、彼はどんな取引からも離れて歩く方が良いだろうと決めました。
反発の台頭
現在米国で確認されているCOVID-19の発生率は240万人で、すでに124,000人の死者が記録されているため、予測は悲惨であり、死者数は20万人に達すると考えられています。厳しい制限があっても、ウイルスは急増しており、完全なロックダウンを永久に実装することは現実的ではありません。
企業、学校、オフィスが再開すると、人々が毎日触れる何百もの表面や物体があります。通勤のボタン、エレベーターのボタン、ドアハンドル、コンピューターのキーパッドなど。目に見えない長持ちするウイルスは、これらの表面のどこにでも存在し、他の表面に簡単に移動し、経済を存続させる人々の命を危険にさらします。
StickSafeはバクテリアやウイルスの拡散を防ぐことができますが、その可能性は数年前には評価されていませんでしたが、今では完全に安全な予防策としての希望を提供しています。このコロナウイルスは世界中で大混乱を引き起こし、少なくとも2年間はピークに達し続けると予想されており、科学者はこれが多くの未知のウイルスや細菌の発生が見られる新しい時代の始まりとなる可能性があると警告しています私たちに。
StickSafeで命を救う
ステッカーに使用されている革新的な素材は無毒で安全であるだけでなく、耐久性にも優れています。 StickSaveは無数の表面やオブジェクトに適用でき、通常の作業条件下で最長60日間持続します。誰かがその表面に触れるたびに、ステッカーはすぐに細菌やバクテリアを中和します。これは、世界中の何百万という人々の潜在的な命の恩人です。
StickSafeの用途は無限であり、飛行機やタクシー、空港、駅、スタジアム、ショッピングモール、レストラン、オフィスエリア、学校、家など、あらゆる輸送モードに配置できます。ワンタッチで、命にかかわるあらゆるものを即座に殺し、ウイルスが次の人に広がるのを防ぎます。
2番目の波の防止
予測された第2波の前に、今こそ予防策を講じる良い機会です。StickSafeを使用すると、すべての領域を安全に保つために必要な作業が少なくなります。現在、人々は消毒剤を持って歩き回っており、漂白剤の販売は急上昇していますが、これには多くの労力と時間がかかり、他の場所で使用することができます。
StickSafeのような製品を使用する明らかな利点はたくさんありますが、最も印象的なのは、ウイルスがどのように変異しても、ステッカーは接触時にすぐに殺され、そのたびに変異に対抗する新しいワクチンの作成を待つ必要がないことです。
先の道に資金を提供する
潜んでいるウイルスや細菌の危険に先んじて、StickSafeの生産はすぐに展開する必要があります。これにより、すべての人、特に高齢者と子供たちの保護が確保されます。
生産を迅速に展開するには、StickSafeがすでに予約済みの専用機械を購入するための財政支援が必要です。Christopher Avinaは、完全に米国で製造された高品質の製品の必要性を強調しています。これにより、アメリカ人の雇用を増やすだけでなく、使用する材料の品質や製造プロセスを管理することもできます。
最後に、StickSafeはCOVID-19に取り組むためのソリューションを世界に提供します。私たちが再び人生をスタートさせようとするとき、StickSafeのドリームチームは、StickSafeを将来に向けて設計し続けることで世界中で命を救うすべてのアメリカの製品にするという課題に取り組む決意です。
Main Press contact:
Christopher Avina, CEO
+1 720 648 6094
CEO@sticksafe.us
Website:
https://www.sticksafe.us/about
https://www.indiegogo.com/projects/sticksafe
Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02
 |
 |
 |
コロラド州デンバーから車でわずか30分で、若いAvinaが数年前にStickSafeを作成しました。このハイテクステッカーは、抗ウイルス性と抗菌性のあるハイテク素材で作られており、私たちがよく触れるあらゆる物体や表面に貼り付けることができます。
Lukewarmレセプション
当時、若いアヴィーナは彼の発見に非常に興奮していました。彼がそれが命を救う可能性があることを知っていたからです。彼は資金調達を模索しましたが、潜在的な投資家が彼の発明にぬるぬるレセプションを与えたことに驚きました。
製品の有用性は明らかでしたが、どこに適用できるか、どのように販売できるかはわかりませんでした。 Avinaは、彼と取引する場合、製品に大幅な変更を要求することもあったことを覚えています。彼の発明をしっかりと信じて、彼はどんな取引からも離れて歩く方が良いだろうと決めました。
反発の台頭
現在米国で確認されているCOVID-19の発生率は240万人で、すでに124,000人の死者が記録されているため、予測は悲惨であり、死者数は20万人に達すると考えられています。厳しい制限があっても、ウイルスは急増しており、完全なロックダウンを永久に実装することは現実的ではありません。
企業、学校、オフィスが再開すると、人々が毎日触れる何百もの表面や物体があります。通勤のボタン、エレベーターのボタン、ドアハンドル、コンピューターのキーパッドなど。目に見えない長持ちするウイルスは、これらの表面のどこにでも存在し、他の表面に簡単に移動し、経済を存続させる人々の命を危険にさらします。
StickSafeはバクテリアやウイルスの拡散を防ぐことができますが、その可能性は数年前には評価されていませんでしたが、今では完全に安全な予防策としての希望を提供しています。このコロナウイルスは世界中で大混乱を引き起こし、少なくとも2年間はピークに達し続けると予想されており、科学者はこれが多くの未知のウイルスや細菌の発生が見られる新しい時代の始まりとなる可能性があると警告しています私たちに。
StickSafeで命を救う
ステッカーに使用されている革新的な素材は無毒で安全であるだけでなく、耐久性にも優れています。 StickSaveは無数の表面やオブジェクトに適用でき、通常の作業条件下で最長60日間持続します。誰かがその表面に触れるたびに、ステッカーはすぐに細菌やバクテリアを中和します。これは、世界中の何百万という人々の潜在的な命の恩人です。
StickSafeの用途は無限であり、飛行機やタクシー、空港、駅、スタジアム、ショッピングモール、レストラン、オフィスエリア、学校、家など、あらゆる輸送モードに配置できます。ワンタッチで、命にかかわるあらゆるものを即座に殺し、ウイルスが次の人に広がるのを防ぎます。
2番目の波の防止
予測された第2波の前に、今こそ予防策を講じる良い機会です。StickSafeを使用すると、すべての領域を安全に保つために必要な作業が少なくなります。現在、人々は消毒剤を持って歩き回っており、漂白剤の販売は急上昇していますが、これには多くの労力と時間がかかり、他の場所で使用することができます。
StickSafeのような製品を使用する明らかな利点はたくさんありますが、最も印象的なのは、ウイルスがどのように変異しても、ステッカーは接触時にすぐに殺され、そのたびに変異に対抗する新しいワクチンの作成を待つ必要がないことです。
先の道に資金を提供する
潜んでいるウイルスや細菌の危険に先んじて、StickSafeの生産はすぐに展開する必要があります。これにより、すべての人、特に高齢者と子供たちの保護が確保されます。
生産を迅速に展開するには、StickSafeがすでに予約済みの専用機械を購入するための財政支援が必要です。Christopher Avinaは、完全に米国で製造された高品質の製品の必要性を強調しています。これにより、アメリカ人の雇用を増やすだけでなく、使用する材料の品質や製造プロセスを管理することもできます。
最後に、StickSafeはCOVID-19に取り組むためのソリューションを世界に提供します。私たちが再び人生をスタートさせようとするとき、StickSafeのドリームチームは、StickSafeを将来に向けて設計し続けることで世界中で命を救うすべてのアメリカの製品にするという課題に取り組む決意です。
Main Press contact:
Christopher Avina, CEO
+1 720 648 6094
CEO@sticksafe.us
Website:
https://www.sticksafe.us/about
https://www.indiegogo.com/projects/sticksafe
|
|
|
Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02
三菱自動車、愛知県蒲郡市と災害時協力協定を締結
本協定の狙いは、災害発生時に改めて自治体と必要事項を確認する時間的ロスをなくし、給電等に活用できるプラグインハイブリッド電気自動車『アウトランダーPHEV』などの電動車を速やかに被災地・避難所等へ届けることです。当社は2022年度までに全国の自治体と災害時協力協定の締結を目指す「DENDOコミュニティサポートプログラム」を推進しており、蒲郡市は55例目となりました。
蒲郡港では、当社岡崎製作所（愛知県岡崎市）とパジェロ製造株式会社（岐阜県坂祝町）で生産した完成車を船積みし、北米などに輸出しています。近年の輸出台数は毎年10万台前後で推移し、2021年には累計250万台に達する見込みです。締結式で当社岡崎製作所長の斉藤 稔は「間もなく達成する250万台という数字は、これまで蒲郡市の皆様に支えられ、積み上げられた成果です。本協定により地域の皆様の安全・安心に寄与できることは、三菱自動車の強い願いです」と述べました。
蒲郡市は協定締結を機に、災害対策に活用する目的で当社製EV『ミニキャブ・ミーブ バン』を1台導入し、2021年度以降も電動車を増やしていく方針です。当社は今後も全国の自治体と足並みを揃えながら、電動車の理解促進・普及や災害時の支援体制強化に向けた取り組みを進めてまいります。
本リリースの詳細は下記をご参照ください。
https://www.mitsubishi-motors.com/jp/newsrelease/2020/detail5444.html
概要：三菱自動車工業株式会社
三菱自動車の企業コミュニケーションワード「Drive@earth」
地球を走る。地球と生きる。三菱自動車。
人とクルマ、社会とクルマ、地球とクルマの新しい時代を拓くために。いま、三菱自動車は挑戦を始めています。走行中のCO2排出ゼロ。地球温暖化防止に貢献する新世代電気自動車、i MiEV（アイミーブ）の世界投入。軽自動車で培った技術を存分に活用、燃費性能にすぐれたグローバル・スモールの提案。世界の環境基準をクリアしながら、走りの楽しさにあふれた三菱ならではの小型ＳＵＶの開発。さらに、新ディーゼルエンジンによるラリー参戦を通じて、走りと環境を両立する、新次元のクルマづくりを追求してゆきます。
私たちは信じています。私たちのクルマへの熱い想いと技術が、新しいクルマの価値をつくることを。ドライブ・アット・アース。走る歓びが永遠であるように。クルマが地球と共生できるように。
詳細はこちらからご覧ください。 www.mitsubishi-motors.co.jp
Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02
7/2/20
Five Advisors With Focus Partner Firm Escala Partners Named to Australia's Top 100 Financial Advisers 2020 List
Escala was established with the collective ambition to become the new standard of personalized wealth management in Australia. The firm quickly emerged as a leading fiduciary wealth advisor to individuals, families, foundations and institutional investors across Australia, providing them with customized investment solutions through a collaborative, team-based approach. Escala's client relationships are sustained over time through their dedication to highly personalized service and an ongoing commitment to innovation in defining the standards for excellence in the Australian wealth management industry.
Mason Allamby, Scott Carmichael, Steve Collins, Amanda Fong and Ben James are Partners and members of the original group of Escala founders who started the firm in 2013. They each have deep expertise in multiple areas of wealth management, including financial planning, asset allocation, tax strategy and, in Ms. Fong's case, the not-for-profit space.
"We are honored to have such an impressive group of our advisors named to the Top 100 Financial Advisors list," said Pep Perry, CEO of Escala. "They embody the collaborative approach and dedication to client service that are the foundation of Escala and make our firm uniquely successful."
"We are thrilled for Escala on receiving this important recognition," said Rajini Kodialam, Co-Founder and Chief Operating Officer of Focus. "Their team of talented advisors are leaders in their field and have been at the forefront of the evolution of the Australian wealth management industry. Their passion for excellence is at the core of everything that they do for their clients and positions them for strong growth in the years ahead."
About Focus Financial Partners Inc.
Focus Financial Partners Inc. is a leading partnership of fiduciary wealth management firms. Focus provides access to best practices, resources, and continuity planning for its partner firms who serve individuals, families, employers and institutions with comprehensive wealth management services. Focus partner firms maintain their operational autonomy, while they benefit from the synergies, scale, economics and best practices offered by Focus to achieve their business objectives. For more information about Focus, please visit www.focusfinancialpartners.com.
About Escala Partners Limited
Founded in 2013, Escala provides objective advice and investment management solutions to high net worth individuals, families, foundations and institutional investors. Escala serves its clients through a collaborative, team-based approach focused on the client experience, a relationship built on trust and sustained over time by performance in line with evolving investment objectives. For more information about Escala, please visit https://escalapartners.com.au.
About The Australia's Top 100 Financial Advisers List 2020 Rankings
Barron's and The Australian's business magazine The Deal rank investment advisers based on client assets managed by the adviser, fees and revenue generated by their business, and the quality of the adviser's business (as measured by factors including the adviser's experience, credentials, client-service resources, and charitable and philanthropic work).
Cautionary Note Concerning Forward-Looking Statements
This release contains certain forward-looking statements that reflect Focus' current views with respect to certain current and future events. These forward-looking statements are and will be, subject to many risks, uncertainties and factors relating to Focus' operations and business environment, including, without limitation, uncertainty surrounding the current COVID-19 pandemic, which may cause future events to be materially different from these forward-looking statements or anything implied therein. Any forward-looking statements in this release are based upon information available to Focus on the date of this release. Focus does not undertake to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any statements expressed or implied therein will not be realized. Additional information on risk factors that could affect Focus may be found in Focus' filings with the Securities and Exchange Commission.
Any services described in this release are not intended for United States persons.
Investor and Media Contact
Tina Madon
Senior Vice President
Head of Investor Relations & Corporate Communications
Focus Financial Partners
P: +1-646-813-2909
tmadon@focuspartners.com
Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com
source http://www.acnnewswire.com/press-release/english/60008/
NEC、しんきん情報サービスと協業し、金融業界初となる為替振込業務の自動化機能を備えた信用金庫向けBPOサービスを提供
金融業界では、膨大なバックオフィス業務に正確性とスピードが求められ、ICTを活用したデジタル化による業務改革の推進が喫緊の課題となっています。なかでも、振込を中心とした為替業務に伴う処理は、為替OCR(Optical Character Reader)帳票の情報を人手で補正・確認しており、効率化が急務です。そこでNECとSISは、振込処理に伴う為替OCR帳票の発信業務の自動化機能を備えた新たなBPOサービスを提供します。
具体的には、まず振込依頼書を特性が異なる2つのOCRエンジンで読み取り、さらに振込先などの過去の取引データを自動で参照することで、判別しにくい文字の読み取りを補助します。また、振込金額や振込指定日等、過去の実績を参照できない情報については、NECとSISが共同で出願済みの特許を用いた独自の方法で誤読を防止します。2つのOCRエンジンが読み取ったそれぞれの結果に対し、補正・確認した結果が最終的に合致すれば発信処理を自動実行します。なお、システム開発は、NECグループのNECソリューションイノベータが担い、過去の取引データの自動参照に関する特許は同社にて出願済みです。本サービスによって、従来人手で行っていた処理のうち、約8割が自動化されます。
NECは、本サービスの機能拡充を推進するとともに、全国の信用金庫をはじめ、地方銀行などさまざまな金融機関への導入を目指します。
NECは、2020年度までの3カ年の中期経営計画「2020中期経営計画」のもと、AIをはじめとする先進技術を活用し、安全で快適な金融サービスを、あらゆる人と産業へ届けるための取り組みを推進します。これにより、人やモノ、プロセスの情報・状態をバリューチェーン全体で共有し、新たな価値を生み出す「NEC Value Chain Innovation」(注3)をお客さまと共に実現していきます。
本リリースの詳細は下記をご参照ください。
https://jpn.nec.com/press/202007/20200703_02.html
概要：日本電気株式会社（NEC)
詳細は www.nec.co.jp をご覧ください。
Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02
NEC、海洋研究開発機構とともに、AIを活用した海洋マイクロプラスチック計測システムを開発
背景
近年、大きさ5mm以下の微小なプラスチック粒子であるマイクロプラスチックによる海洋汚染が世界的に拡大しており、生態系への影響だけではなく、食物連鎖を通じた人体への悪影響が懸念されています。海洋マイクロプラスチック汚染の実態を正確に把握するためには、各海域におけるマイクロプラスチックの数・大きさ・種類を分析することで、流出源を推定し、流出経路・到達地を予測する必要があります。
これまでの調査手法は、海水や前処理を施した堆積物などを目の細かい網ですくい、その中からマイクロプラスチックを顕微鏡などを用いて一粒ずつ手作業で拾い出して分析するのが⼀般的でした。しかし、これには膨大な時間と手間がかかるだけでなく、一般的に用いられている網の目をすり抜ける300um以下の微⼩な粒⼦を過小評価してしまうという課題がありました。
JAMSTECは、海洋科学技術の総合的な研究を行う国立研究開発法人であり、従来から海洋マイクロプラスチックを検出する分析技術の研究開発に取り組んでいます。今回NECは、最先端AI技術群「NEC the WISE」(注2)のディープラーニング技術を搭載した「RAPID機械学習」(注3)による画像認識技術で、マイクロプラスチックを高速かつ高精度に検出・分類する仕組みを提供しました。あわせて、蛍光顕微鏡で撮影したマイクロプラスチックが試料中を流れる動画から、AI連携のための画像を抽出してデータ化するソフトウェアも提供しました。
具体的には、JAMSTECのこれまでの研究開発の知見を活かし、海水や前処理をした堆積物など試料中のマイクロプラスチックを蛍光色素で染色し、検出に最適な速度で流しながら、蛍光顕微鏡で動画を撮影します。次に、今回開発したソフトウェアにより、この動画からマイクロプラスチック一つひとつを画像データとして自動抽出します。さらにAIによる画像認識技術を活用することで、毎分60個の処理速度で、サイズや形状を自動的に分類・集計することが可能となりました。これにより、これまで手作業で行なってきたマイクロプラスチックの検出を、自動化・高精度化することを実現しています。
今後この計測手法が確立されて普及することで、マイクロプラスチック汚染の実態解明が進み、適切な排出規制の立案に貢献できることが期待されます。
NECは従来から、JAMSTECのスーパーコンピュータ「地球シミュレータ」を利用した「沿岸災害シミュレーションシステム」の研究開発(注4)や、AIを活用した微化石の正確な鑑定・分取技術の確立(注5)などに取り組んできました。今後もAIをはじめとした先進技術の活用によって社会全体の環境負荷低減に貢献する「環境経営」を通して、持続可能な社会の実現を目指します。
本リリースの詳細は下記をご参照ください。
https://jpn.nec.com/press/202007/20200703_01.html
概要：日本電気株式会社（NEC)
詳細は www.nec.co.jp をご覧ください。
Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02
Gynesys Best Home Security Urges Businesses to Work with African-American Owned Commercial Security Firms in the Aftermath of CPI Security CEO's Remarks; Prepared to Work with Carolina Panthers, Charlotte Hornets to Replace CPI as Major Sponsor
"The comments made by Mr. Gill were perceived by many to be extremely racist and emblematic of the broader issue of lack of diversity and inclusion in the security industry. I know that we as Americans can make a difference both in large ways and in small ways. Supporting black owned businesses, while it may be perceived as a small decision, has a big impact on our community," said Solomon Ali, CEO of Revolutionary Concepts Inc., parent company of Gynesys Best Home Security and owner of multiple patents on smart home technology.
Gynesys is gearing up for a major marketing and advertising campaign to encourage prospective customers to make the switch. As part of that campaign, company executives including Mr. Ali plan to reach out to the Carolina Panthers and the Charlotte Hornets as they are planning to replace CPI Security as a major sponsor of the sports franchises.
Black Wealth Matters, an Atlanta-based group dedicated towards building an economically inclusive America encouraged consumers and companies of conscience to support black businesses as a means to remedy the horrifying instances of police violence and economic inequality.
"Individuals and companies who do business with Gynesys and other black owned businesses are helping to support a positive movement to build wealth in the African American community, create black jobs, and build a fairer America that is better for ALL of us regardless of color. I encourage businesses and sports franchises including the Charlotte Hornets and the Carolina Panthers to partner with Gynesys to provide top-notch security equipment and to highlight what we can achieve when we support diverse businesses," said Arletta Saafir, Executive Director of Black Wealth Matters.
Gynesys's parent company Revolutionary Concepts Inc., holds the Intellectual Property to its smart home technology. This patented technology is used in today's smart homes utilizing two-way audio/video communication with security alarm and mobile video communication technology. Eyetalk 365, (the exclusive licensee), has licensed its technology to many companies such as Axis, CPI, Sky Bell, and RING (owned by Amazon), and many others. Unfortunately, there are other companies using this patented technology without a licensing agreement therefore engaging in patent infringement. While many licensors of Intellectual Property suffer from patent infringement, the fact that Revolutionary Concepts is a black-owned enterprise has been a major factor in why many large businesses fail to pay what they owe.
Gynesys Best is currently offering a promotion allowing residential and commercial customers to get free security systems along with delivery and installation with our completive monthly prices. Additional discounts are offered for veterans, first-responders, and church groups. For more information, please visit https://www.gynesyshomeautomation.com/
Contact:
Bethiel Tesfasillasie, Chief Operating Officer
Gynesys Best Home Security
877-558-3431
support@gynesysbesthomesecurity.com
https://www.gynesyshomeautomation.com/
This press release was issued through EmailWire.Com - the global newswire with press release distribution services. For more information, go to http://www.emailwire.com.
Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com
source http://www.acnnewswire.com/press-release/english/59992/
Singapore's Leading B2B Tech Event Stack Rescheduled to 2021
Originally planned to be held this October at Marina Bay Sands, the event stack was expected to see over 21,000 professionals in attendance, 400+ leading technology providers showcase their latest solutions, and 600+ expert speakers congregate to share the latest technological advancements and ideas.
The organiser's final decision of postponement was made after extensive consultation with government authorities and stakeholders, with the primary objective to safeguard the health and wellbeing of exhibitors and attendees.
With regards to the postponement, Managing Director, Andy Kiwanuka said, "Our stakeholders have come to expect an excellent experience at the business event each year, and we are committed to delivering on that expectation while ensuring everyone's safety. Thus, rescheduling the events is the only responsible course of action at this point. We appreciate everyone's support and understanding throughout this challenging time, and remain excited to bring to you Cloud Expo Asia and the co-located events in 2021."
Separately, as part of CloserStill Media's continued community engagement in Singapore, the organiser will host various "Thought Leadership Series" events incorporating virtual executive fireside chats, high-level digital round tables, targeted content-led marketing, as well as sector-specific mini tech events (physical and virtual) in early 2021.
CloserStill Media's next Technology event in Asia will be the return of Cloud Expo Asia, Hong Kong on the 23rd - 24th September 2020. Celebrating its 5th anniversary as the leading Tech industry event in the region, this edition will be the first hybrid version of the event (physical and virtual).
The organiser will closely monitor the coronavirus situation in collaboration with the government, health authorities and venues, to ensure a high level of hygiene and safety at the world-class events in September 2020 and October 2021. The team will be in touch with all confirmed exhibitors, speakers and partners to discuss their participation at the rescheduled events.
For urgent assistance, please email ceamarketing@closerstillmedia.com.
For more information on Cloud Expo Asia, Singapore and the co-located events, visit www.cloudexpoasia.com
Updates about the events will be shared on the following social media pages:
LinkedIn: www.linkedin.com/company/cloudexpoasia/
Facebook: www.facebook.com/CloudExpoAsia
Instagram: www.instagram.com/singaporetechshows/
For media enquiries, kindly contact Nic-cole Chia at n.chia@closerstillmedia.com.
About CloserStill Media
CloserStill Media specializes in international professional events chiefly in the technology markets, across five global territories. Its portfolio includes some of the UK's fastest-growing and award-winning events including Cloud Expo Europe and Data Centre World. Having delivered unparalleled quality and relevant audiences for all its exhibitions, CloserStill Media has been repeatedly recognized as a leading innovator with its teams and international events winning multiple awards in Europe and Asia including Best Marketing Manager - four times in succession - Best Trade Exhibition, Best Launch Exhibition, and Rising Star - two years in succession - among others.
For more information, visit www.closerstillmedia.com.
Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02
ベルシステム24とソニーCSL、独自開発の人工知能（AI）技術によるコンタクトセンター運用に特化したサービスの提供を開始
このサービスは、コンタクトセンター業務での利用に特化した高精度なAI検索エンジン「Mopas(TM)(モーパス)」と、AIナレッジメンテナンス機能「Knowledge Creator(TM)(ナレッジクリエーター：特許出願中)」で構成され、顧客からのメールでの問い合わせ対応業務の効率化と削減につなげるものです。
「Mopas(TM)」はクライアント企業が保有するコンタクトセンターのFAQデータのみをベースに、数十万種類のアルゴリズム・パラメーターから正答率の高い組み合わせを採用した最適なAIモデルを数時間で自動生成します。一般的にコンタクトセンター向け自動対応システムには、業種ごとに特定のAIアルゴリズムを使い、顧客との電話やメールやチャット等様々なデータを必要としてきましたが、「Mopas(TM)」は投入データ量を限定しながらも、膨大かつ多様性あるアルゴリズムにより最適解を導き出すことを可能としています。さらに、本年4月にベルシステム24内に設立した「イノベーション＆コミュニケーションサイエンス研究所」にて継続的にAIの研究成果を評価・検証しており、常に最新のアルゴリズムにアップデートされたAI検索エンジンの利用が可能となります。
「Knowledge Creator(TM)」は、直感的なユーザーインターフェースに統合されたクラスタリング（類似度に基づいてデータをグループ分けする手法）や検索キーワードのサジェスト・類似問い合わせの提示などにより、従来表計算ソフトを用いた属人的な作業であった教師データ追加作業やFAQ等のナレッジ管理・更新作業を大幅に効率化できるものです。この「Knowledge Creator(TM)」と「Mopas(TM)」が連携することで検索精度とナレッジのカバレッジが日々向上していきます。
この二つの新開発AIソリューションにより、各クライアント企業の業種・業態に特化した、常にアップデートされた最適なカスタマーサービスを実現するAIの活用が可能になるとともに、導入並びに運用コストの抑制を実現できるようになります。なお、本サービスにおいて、ベルシステム24は、主に顧客向け製品開発、営業活動を担い、ソニーCSLは、AIのアルゴリズム開発などの機能・性能向上のための研究開発を推進します。
■試験運用における本ソリューションの導入効果
当サービスは、過去１年間以上の試験運用を実施しており、メーカーや通信事業者などの各クライアント企業のカスタマーサポート分野において、その有効性を確認しながら、検証とシステム改善を積み重ねてきました。数社での試験運用におけるクライアント企業での導入実績として、メールの問い合わせ件数69.7％の削減や、FAQカバレッジの40％以上の向上などの成果をあげています。
■開発背景
昨今、コンタクトセンターに寄せられる生活者からの問い合わせは、電話だけでなく、Eメール・チャットなど複数のコミュニケーション手段が使用されており、企業において、それぞれへの対応整備は難易度を増しています。
これまでも様々なAI検索エンジンがコンタクトセンターにおいて運用されてきましたが、通常は特定のアルゴリズムが搭載されているため、業種・業態により相性が異なり、パフォーマンスに大きなばらつきが見られていました。また、一度AI検索エンジンとして構築されると、世界中で日々進化を続ける最先端のアルゴリズムへの対応が出来ない点や、データのメンテナンスやナレッジのアップデートに多くの人的コストが発生する点も課題でした。
これらの課題を解決し、実務に沿ったカスタマーサービスの運用業務に最適なAIを開発すべく、ベルシステム24のコンタクトセンターの現場における業務フローの知見と、ソニーCSLのAI研究の知見を組み合わせ、共同で独自のAIソリューションを開発するに至りました。この取り組みを皮切りに、両社の強みやノウハウを活用して、コンタクトセンター運用における業務効率向上やコミュニケーターの負担軽減、顧客の利便性向上を目指します。
■松田 裕弘
株式会社ベルシステム24ホールディングス 執行役員CIO、
同イノベーション＆コミュニケーションサイエンス研究所 所長のコメント
「コンタクトセンターAIを広く普及し、多くの方にそのメリットを享受頂くためにはナレッジ管理の高度化、標準化は重要なテーマです。今回、「Mopas(TM)」の高いアルゴリズム精度に加えて、ナレッジのカバレッジを高める「Knowledge Creator(TM)」の提供によって、その第一歩を踏み出すことができました。今後も、我々「イノベーション＆コミュニケーションサイエンス研究所」では、"ベルシステム２４の現場力"と"ソニーCSLの技術力"という課題発見・実験・検証・製品化に最適な組み合わせによって、第二、第三の解決策を研究開発として進め、その成果を製品という形で提供し続けてまいります。」
■ミカエル・ シュプランガー
株式会社ソニーコンピュータサイエンス研究所 リサーチャー、株式会社ソニーAI COO
イノベーション＆コミュニケーションサイエンス研究所 共同研究所長のコメント
「ユーザーと企業の直接的な接点となるコンタクトセンターは、顧客満足度とリテンション向上を左右する最前線にあります。企業がこれまで以上に積極的にユーザーを支援し、洞察を得て長期的な関係を構築できるようにするために、AIが果たす役割はますます大きくなると考えます。一方でAIは技術として進化の過程にあり、新しい成果が日々発表されています。このような状況下でAIを有効に活用するためには、データを中心に据えた好循環のイノベーションサイクルを生み出すことが必要であり、それと共に、データを多く持っていない企業でもAIを活用できることが重要です。これらを実現すべく、最先端のAIアルゴリズムを使用した業界最高クラスのパフォーマンスを提供する「Mopas(TM)」と、必要なデータの作成・維持・更新のための具体的な道筋を提供する「Knowledge Creator(TM)」を開発しました。今後も、これらのシステムの有用性を高める機能を追加していきます。」
株式会社ベルシステム24ホールディングスについて
1982年に国内初の本格的コールセンターサービスを開始し、現在では日本全国に国内No.1となる36拠点を設置し、約17,000席のブースを有しています。2014年に伊藤忠商事、2017年に凸版印刷と資本・業務提携を締結し、新たな事業機会とサービスの創造を図っています。クライアント企業にとっての「ベストCXパートナー」であり続けることを目指し、高いサービス品質を提供する高度人材育成並びに最先端のAI・RPAなど新技術によりコミュニケーター支援を行う次世代コンタクトセンター構築を進めています。その一環として、本年、ソニーコンピュータサイエンス研究所から共同研究所長を迎え、社内R&D組織である「イノベーション＆コミュニケーションサイエンス研究所(ICS Lab.)」を設立しました。
URL：https://www.bell24hd.co.jp/
株式会社ソニーコンピュータサイエンス研究所について
1988年に設立されたソニーの研究所。新たな研究領域や研究パラダイム、新技術や新事業を創出し、人類・社会に貢献することを目的としています。現在は、 農業、都市計画、エネルギー、また医療などの社会課題を扱うグローバル・アジェンダ、人間の能力拡張（Human Augmentation/Creativity）、そしてAI、データサイエンスを主な研究テーマとしています。東京に加えて京都、パリに支所があります。
URL：https://www.sonycsl.co.jp/
本リリースの詳細は下記をご参照ください。
https://www.sonycsl.co.jp/press/prs20200702/
概要：ソニー
詳細は www.sony.co.jp をご覧ください。
Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02
7/1/20
Singapore's Leading B2B Tech Event Stack Rescheduled to 2021
Originally planned to be held this October at Marina Bay Sands, the event stack was expected to see over 21,000 professionals in attendance, 400+ leading technology providers showcase their latest solutions, and 600+ expert speakers congregate to share the latest technological advancements and ideas.
The organiser's final decision of postponement was made after extensive consultation with government authorities and stakeholders, with the primary objective to safeguard the health and wellbeing of exhibitors and attendees.
With regards to the postponement, Managing Director, Andy Kiwanuka said, "Our stakeholders have come to expect an excellent experience at the business event each year, and we are committed to delivering on that expectation while ensuring everyone's safety. Thus, rescheduling the events is the only responsible course of action at this point. We appreciate everyone's support and understanding throughout this challenging time, and remain excited to bring to you Cloud Expo Asia and the co-located events in 2021."
Separately, as part of CloserStill Media's continued community engagement in Singapore, the organiser will host various "Thought Leadership Series" events incorporating virtual executive fireside chats, high-level digital round tables, targeted content-led marketing, as well as sector-specific mini tech events (physical and virtual) in early 2021.
CloserStill Media's next Technology event in Asia will be the return of Cloud Expo Asia, Hong Kong on the 23rd - 24th September 2020. Celebrating its 5th anniversary as the leading Tech industry event in the region, this edition will be the first hybrid version of the event (physical and virtual).
The organiser will closely monitor the coronavirus situation in collaboration with the government, health authorities and venues, to ensure a high level of hygiene and safety at the world-class events in September 2020 and October 2021. The team will be in touch with all confirmed exhibitors, speakers and partners to discuss their participation at the rescheduled events.
For urgent assistance, please email ceamarketing@closerstillmedia.com.
For more information on Cloud Expo Asia, Singapore and the co-located events, visit www.cloudexpoasia.com
Updates about the events will be shared on the following social media pages:
LinkedIn: www.linkedin.com/company/cloudexpoasia/
Facebook: www.facebook.com/CloudExpoAsia
Instagram: www.instagram.com/singaporetechshows/
For media enquiries, kindly contact Nic-cole Chia at n.chia@closerstillmedia.com.
About CloserStill Media
CloserStill Media specializes in international professional events chiefly in the technology markets, across five global territories. Its portfolio includes some of the UK's fastest-growing and award-winning events including Cloud Expo Europe and Data Centre World. Having delivered unparalleled quality and relevant audiences for all its exhibitions, CloserStill Media has been repeatedly recognized as a leading innovator with its teams and international events winning multiple awards in Europe and Asia including Best Marketing Manager - four times in succession - Best Trade Exhibition, Best Launch Exhibition, and Rising Star - two years in succession - among others.
For more information, visit www.closerstillmedia.com.
Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com
source http://www.acnnewswire.com/press-release/english/59997/
TOYOTA、ポルテならびにスペイドに安全・安心装備を充実させた特別仕様車を設定
今回の特別仕様車は、ポルテならびにスペイドの「F」、「G」をベースに、駐車場などでのアクセルとブレーキの踏み間違いやアクセルの踏み過ぎなどで起こる衝突被害の軽減に寄与するインテリジェントクリアランスソナー［パーキングサポートブレーキ（静止物）］を特別装備。さらに、後退時に後方の視界をナビゲーション画面に表示するバックカメラを含むナビレディパッケージ＊1、太陽光に近い色と大光量で夜間の運転をアシストするディスチャージヘッドランプ＊2などを含むHIDパッケージ＊3を特別装備し、安全・安心装備を充実させています。
ポルテには、外板色にホワイトパールクリスタルシャイン（オプション）を含む全4色、内装色に明るいフロマージュを設定。スペイドには、外板色にボルドーマイカメタリックを含む全4色、内装色にシックなプラムを設定しました。
本リリースの詳細は下記URLをご参照ください。
https://global.toyota/jp/newsroom/toyota/33008957.html
概要：トヨタ自動車株式会社
詳細は http://toyota.jp/ をご覧ください。
Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02
NEC、生体認証・映像分析技術とサーマルカメラを組み合わせた感染症対策ソリューションを販売開始
新型コロナウイルス感染症が世界的に拡大し、人々の暮らしや経済活動に大きな影響を与えています。また、社会の在り方がNew Normalへと変革していく中、経済活動を継続する上で人が集まる場所での効果的な対策が求められています。
NECは、生体認証「Bio-IDiom」(注1)の中核技術であり世界No.1の認証精度(注2)を有する顔認証技術、施設の混雑度を見える化する映像分析技術、体表温度を非接触で測定するサーマルカメラを組み合わせて、人が密集する場所での水際対策と感染リスク低減に貢献するソリューションを提供します。
NECは、以下の機能をお客様のニーズや環境に合わせ、柔軟に組み合わせてソリューションとして提供します。
1. 水際対策に適した非接触の体表温度測定、顔認証入場管理
顔検出技術とサーマルカメラを組み合わせることで、来訪者の体表温度の測定を非接触かつスムーズに実現します(特許取得済、注3)。また顔認証技術も活用することで、施設への入場時に設定値以上の体表温度が確認された場合は、対象者の顔情報と併せて管理者に通知し検温を促すこともできます。学校や企業においては、日々の情報を蓄積することで健康管理や労務管理などにも役立てることができます。なおサーマルカメラについては、日本アビオニクス社(注4)の協力により、高精度な体表温度の測定を可能としています。また、本ソリューションは、人権・プライバシー保護の観点から、導入するお客様が顔認証技術の利用について本人の同意を得ることを前提としています。
2. 施設内での感染リスク低減を支援する、人数カウント、混雑度モニタリング、マスク未着用者検知機能
映像分析技術を活用した施設内の人数カウントと混雑度モニタリングにより、入場者数の管理、サイネージへの混雑度表示、管理者への通知などを行うことができます。これにより、来場者へのソーシャルディスタンスの喚起や誘導を行うことも可能となるため、密集の抑止を実現します。また、映像からマスク着用の有無をリアルタイムに検知することで、未着用者にサイネージを通じて気づきを与えたり、管理者に通知して直接声がけを行ったりすることで、感染リスクの低減を支援します。
NECは本年8月末より、体表温度測定を基本機能として備えたベーシックなモデルを提供するとともに、混雑度モニタリングやマスク未着用者検知などの機能を拡充したモデルも順次発売予定です。これらにより、職場・教育機関・公共施設・商業施設・イベント会場・テーマパークといった人が密集する場所で、クラスター発生防止など感染症対策に貢献することを目指します。
本リリースの詳細は下記をご参照ください。
https://jpn.nec.com/press/202007/20200702_01.html
概要：日本電気株式会社（NEC)
詳細は www.nec.co.jp をご覧ください。
Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02
MOG Recorded a YOY Earnings Growth for the year ended 31 March 2020 by leveraging its extensive retail network and strong brand recognition to capture new market opportunities
HONG KONG, Jul 2, 2020 - (ACN Newswire) - MOG Holdings Limited (Stock code: 1942.HK), one of the largest retailers of optical products in Malaysia in term of revenue, is pleased to announce its annual results for the year ended 31 March 2020 (the "Reporting Period").
Highlights of Earning Results for the Year Ended 31 March 2020
- Revenue recorded steady year-on-year (YOY) growth of approximately 10.1% to RM147.1 million
- Gross profit increased by 15.8% YOY to approximately RM97.3 million while gross profit margin grew YOY by 3.3 percentage points to approximately 66.1%
- Excluding listing expenses of approximately RM9.8 million during the Reporting Period, the adjusted profit for the Reporting Period reached approximately RM23.6 million, up 3.5% YOY
- MOG's retail network further expanded in Malaysia: the number of self-owned retail stores increased to 83 as at 31 March 2020, for a net increase of 8 self-owned retail stores as the retail store network in Malaysia further expanded
- Gearing ratio decreased from approximately 0.37 times as at 31 March 2019 to approximately 0.30 times as at 31 March 2020
During the Reporting Period, the outbreak of COVID-19 impacted the Malaysian economy as the Malaysian Government implemented its Movement Control Order ("MCO") which was initially in effect from 18 March 2020 until 31 March 2020. However, MOG was able to leverage its extensive retail network and successful multi-brand strategy to achieve a steady YOY growth of revenue, gross profit and adjusted profit (excluding the impact of listing expenses) for the Year during the Reporting Period. The Group's increase in revenue was mainly driven by MOG's retailing business which experienced YOY growth of approximately 10.0%, which was primarily due to the increase in the sales volume of the Group's optical products resulting from the continuous expansion of the Group's retail network. During the Reporting Period, MOG had a retail network added 8 self-owned retail stores, bringing the total self-owned retail stores to 83. As at 31 March 2020, MOG's retail network, which comprised 83 self-owned, 10 franchised and two licensed retail stores, were located across Central, Southern, Northern and Eastern Peninsula Malaysia.
Given that the outbreak of COVID-19 pandemic continued in April, the MCO was further extended to 3 May 2020. Subsequently, the Malaysian Government implemented a conditional MCO on 4 May 2020 through 9 June 2020 allowing certain business sectors, including the optical retail industry, to resume operations. On 18 March 2020, MOG temporarily closed all its self-owned retail stores as part of the management efforts to ensure the health and safety of its employees and customers. From 5 May 2020, MOG gradually resumed its business operation, and all self-owned retail stores resumed business by 13 May 2020. The Malaysian Government has implemented a recovery MCO from 10 June 2020 to 31 August 2020, which has fewer restrictions on daily activities and allows interstate travel. In light of the above, MOG is reviewing its monthly expenses and will adopt measures to reduce its operating costs as well as negotiate with landlords for rental rebate/reduction during these periods.
As at 31 March 2020, the Group had bank balances and cash of approximately RM34.1 million and fixed deposit with a licensed bank of approximately RM4.0 million. In addition, the Group raised approximately HKD91.1 million from its global offering pursuant to the Listing on the Main Board of the HKEx. As such, MOG believes that the Group has adequate working capital to meet its present and foreseeable expenses for the next 12 months.
Leading player to capture new opportunities in Malaysian eyewear retail market
According to the Central Bank of Malaysia, Malaysia's economic growth, as measured by Gross Domestic Product (GDP), is projected to be between -2% to +0.5% in 2020 as a result of the highly challenging global economic outlook due to the COVID-19 pandemic. In addition to the pandemic, the domestic economy is also being affected by a sharp decline and volatility in crude oil prices and continued supply disruption in the commodities sector. However, MOG believes a gradual rebound of pedestrian footfall can be seen for its retail network if the MCO and border restrictions are loosened. In addition, MOG remains positive given its sufficient working capital, extensive retail network, established reputation, diversified portfolio of optical products, as well as the growing demand for optical products
Looking forward, MOG believes that increasing awareness of eyecare will continue to drive the development of the eyewear retail market in Malaysia. With the number of people impacted by visual impairment expected to continue to expand, specifically myopia in children and teenagers due to long-term use of technological devices, such as smartphones, tablets and computers, the demand for optical products, particularly prescription glasses and contact lenses is also expected to increase. Furthermore, while the economy faces many challenges, MOG with its strong competitive advantages, solid financial position and extensive retail network, combined with its established brand, will capture new opportunities arising from Malaysia's economy recovery as the Group continues strengthening its leading industry position in Malaysian eyewear retail market.
MOG Holdings Limited
MOG Holdings Limited is one of the largest retailers of optical products in Malaysia in terms of revenue. The Group offers a wide range of optical products which generally include lenses, frames, contact lenses and sunglasses from International Brands (being the brands of optical products generally from or which generally carry the trademarks of (i) international luxury fashion and optical brands; and (ii) international high-street fashion and optical brands), the Group's Own Brands (being the brands of optical products which carry the Group's trademarks and are manufactured by third party manufacturers) and Manufacturers' Brand (being the brands of optical products which are designed and manufactured by third party manufacturers).
As at 31 March 2020, the Group's retail network, which comprised 83 self-owned, 10 franchised and 2 licensed retail stores located across Central, Southern, Northern and Eastern Peninsula Malaysia.
Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com
source http://www.acnnewswire.com/press-release/english/59989/
Highlights of Earning Results for the Year Ended 31 March 2020
- Revenue recorded steady year-on-year (YOY) growth of approximately 10.1% to RM147.1 million
- Gross profit increased by 15.8% YOY to approximately RM97.3 million while gross profit margin grew YOY by 3.3 percentage points to approximately 66.1%
- Excluding listing expenses of approximately RM9.8 million during the Reporting Period, the adjusted profit for the Reporting Period reached approximately RM23.6 million, up 3.5% YOY
- MOG's retail network further expanded in Malaysia: the number of self-owned retail stores increased to 83 as at 31 March 2020, for a net increase of 8 self-owned retail stores as the retail store network in Malaysia further expanded
- Gearing ratio decreased from approximately 0.37 times as at 31 March 2019 to approximately 0.30 times as at 31 March 2020
During the Reporting Period, the outbreak of COVID-19 impacted the Malaysian economy as the Malaysian Government implemented its Movement Control Order ("MCO") which was initially in effect from 18 March 2020 until 31 March 2020. However, MOG was able to leverage its extensive retail network and successful multi-brand strategy to achieve a steady YOY growth of revenue, gross profit and adjusted profit (excluding the impact of listing expenses) for the Year during the Reporting Period. The Group's increase in revenue was mainly driven by MOG's retailing business which experienced YOY growth of approximately 10.0%, which was primarily due to the increase in the sales volume of the Group's optical products resulting from the continuous expansion of the Group's retail network. During the Reporting Period, MOG had a retail network added 8 self-owned retail stores, bringing the total self-owned retail stores to 83. As at 31 March 2020, MOG's retail network, which comprised 83 self-owned, 10 franchised and two licensed retail stores, were located across Central, Southern, Northern and Eastern Peninsula Malaysia.
Given that the outbreak of COVID-19 pandemic continued in April, the MCO was further extended to 3 May 2020. Subsequently, the Malaysian Government implemented a conditional MCO on 4 May 2020 through 9 June 2020 allowing certain business sectors, including the optical retail industry, to resume operations. On 18 March 2020, MOG temporarily closed all its self-owned retail stores as part of the management efforts to ensure the health and safety of its employees and customers. From 5 May 2020, MOG gradually resumed its business operation, and all self-owned retail stores resumed business by 13 May 2020. The Malaysian Government has implemented a recovery MCO from 10 June 2020 to 31 August 2020, which has fewer restrictions on daily activities and allows interstate travel. In light of the above, MOG is reviewing its monthly expenses and will adopt measures to reduce its operating costs as well as negotiate with landlords for rental rebate/reduction during these periods.
As at 31 March 2020, the Group had bank balances and cash of approximately RM34.1 million and fixed deposit with a licensed bank of approximately RM4.0 million. In addition, the Group raised approximately HKD91.1 million from its global offering pursuant to the Listing on the Main Board of the HKEx. As such, MOG believes that the Group has adequate working capital to meet its present and foreseeable expenses for the next 12 months.
Leading player to capture new opportunities in Malaysian eyewear retail market
According to the Central Bank of Malaysia, Malaysia's economic growth, as measured by Gross Domestic Product (GDP), is projected to be between -2% to +0.5% in 2020 as a result of the highly challenging global economic outlook due to the COVID-19 pandemic. In addition to the pandemic, the domestic economy is also being affected by a sharp decline and volatility in crude oil prices and continued supply disruption in the commodities sector. However, MOG believes a gradual rebound of pedestrian footfall can be seen for its retail network if the MCO and border restrictions are loosened. In addition, MOG remains positive given its sufficient working capital, extensive retail network, established reputation, diversified portfolio of optical products, as well as the growing demand for optical products
Looking forward, MOG believes that increasing awareness of eyecare will continue to drive the development of the eyewear retail market in Malaysia. With the number of people impacted by visual impairment expected to continue to expand, specifically myopia in children and teenagers due to long-term use of technological devices, such as smartphones, tablets and computers, the demand for optical products, particularly prescription glasses and contact lenses is also expected to increase. Furthermore, while the economy faces many challenges, MOG with its strong competitive advantages, solid financial position and extensive retail network, combined with its established brand, will capture new opportunities arising from Malaysia's economy recovery as the Group continues strengthening its leading industry position in Malaysian eyewear retail market.
MOG Holdings Limited
MOG Holdings Limited is one of the largest retailers of optical products in Malaysia in terms of revenue. The Group offers a wide range of optical products which generally include lenses, frames, contact lenses and sunglasses from International Brands (being the brands of optical products generally from or which generally carry the trademarks of (i) international luxury fashion and optical brands; and (ii) international high-street fashion and optical brands), the Group's Own Brands (being the brands of optical products which carry the Group's trademarks and are manufactured by third party manufacturers) and Manufacturers' Brand (being the brands of optical products which are designed and manufactured by third party manufacturers).
As at 31 March 2020, the Group's retail network, which comprised 83 self-owned, 10 franchised and 2 licensed retail stores located across Central, Southern, Northern and Eastern Peninsula Malaysia.
Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com
source http://www.acnnewswire.com/press-release/english/59989/
Hua Medicine Announces Positive 24-Week Topline Results of Phase III Metformin Combination Trial of Dorzagliatin
SHANGHAI, CHINA, Jul 1, 2020 - (ACN Newswire) - Hua Medicine today announced the positive 24-week top-line results from HMM0302, a Phase III registration trial in China of its global first-in-class glucokinase activator dorzagliatin add-on to metformin, a first line oral antidiabetic therapy in Type 2 diabetes. All subjects are treated with metformin (Glucophage) at 1500mg/day as basic therapy throughout the entire 52-week treatment period. These patients are also given either twice-daily doses of dorzagliatin (75mg) or placebo, randomized on a 1:1 ratio. The clinical study evaluates the efficacy and safety of dorzagliatin during 24 weeks of double-blinded treatment, followed by a subsequent 28-week open-label treatment period when all patients will receive dorzagliatin 75mg twice daily. The primary efficacy endpoint is evaluated at the conclusion of the first 24 weeks. The subsequent 28-week treatment period is ongoing.
- Met the primary efficacy and safety endpoints in the double-blinded placebo-controlled and randomized 24-week trial
- Dorzagliatin again demonstrated fast onset, potent and sustained HbA1c reduction of 1.02% from baseline at 24-week, and is superior over placebo treated group by 0.66% with a p-value less than 0.0001, in T2D patients whose blood glucose cannot be controlled with the maximum dose of metformin (1500mg/day).
- High response rate was observed in the treatment group with 44.4% of patients having achieved HbA1c level below 7% at 24-week
- Statistically significant improvements in HbA1c response rate, HOMA2-beta and HOMA2-IR, 2hPPG and FPG, were observed in the dorzagliatin-treated group over the placebo group
- Clinically significant hypoglycemia incidence rate is less than 1% in the 24-week treatment period
- In the 24-week treatment period, dorzagliatin demonstrated a well-tolerated and good safety profile. There was no drug-related SAE, nor severe hypoglycemia reported
In 766 Type 2 diabetes patients whose blood glucose cannot be controlled with the maximum tolerated dose of equal or greater than 1500 mg/day of metformin, dorzagliatin demonstrated fast onset, potent and sustained HbA1c reduction of 1.02% (least squares mean) from baseline at 24-week, as compared to a reduction of 0.36% (least squares mean) from baseline for the placebo group (p-value less than 0.0001, 95% CI between -0.79 to -0.53).
The American Diabetes Association (ADA) treatment target of HbA1c below 7.0%was achieved by 44.4% of subjects on dorzagliatin and metformin, compared to 10.7% of subjects who received metformin only. Patients treated with dorzagliatin demonstrated statistically significant improvement of HOMA2-beta, HOMA2-IR, 2hPPG and FPG over those in the placebo group.
In the 24-week period, dorzagliatin continued to exhibit a safe and well-tolerated clinical profile. There was less than 1% hypoglycemia with blood glucose < 3 mmol/L during the 24-week treatment period. There was no drug-related SAE, nor severe hypoglycemia reported.
"I am very pleased to see dorzagliatin provided very good glycemic control in the metformin-failed Type 2 diabetes patients in China," said Dr. Wenying Yang of the China-Japan Friendship Hospital and lead principal investigator of HMM0302 clinical study. "It offers a new solution to many patients whose blood glucose cannot be controlled with maximum tolerated dose of metformin, the first line therapy currently used for T2D treatment worldwide. I am very impressed by the determination and execution of Hua Medicine during the clinical trials, consistent with global standards, which leads to the high quality results in the 24-week period of HMM0302 trial."
"I am very excited to see the success in the HMM0302 clinical study. It will expand dorzagliatin into a very large patient population and help millions of T2D patients who failed in metformin treatment. It further supports our strategy to add dorzagliatin as a cornerstone therapy to current therapies including metformin, and DPP-IV inhibitors or SGLT-2 inhibitors, as well as GLP-1 and insulin. It will immediately expand our drug product pipeline based on the combination therapies," said Dr. Li Chen, CEO of Hua Medicine. "Through repairing the glucose sensor and improving the glucose sensitivity which addressed the underlying cause of T2D, dorzagliatin provides the synergy with existing antidiabetic medicines to better control diabetes. This is the first step to systematically address the heterogenic nature of T2D and provide a solution in personalized diabetes care."
Hua Medicine is planning to file an NDA in China after completing the second stage of the HMM0302 52-week study and developing one or more partnership to commercialize dorzagliatin in China and the rest of the world.
HMM0302 study design
HMM0302 Study is a randomized, double-blind, placebo-controlled Phase III study in 766 Type 2 diabetes patients inadequately glycemic controlled with metformin. Subjects are treated with metformin (Glucophage) at 1500mg/day as basic therapy throughout the whole 52-week treatment period. Patients are given twice-daily doses of dorzagliatin (75mg) or placebo, randomized on a 1:1 ratio. The clinical study evaluates the efficacy and safety of dorzagliatin during 24 weeks of double-blinded treatment, followed by a subsequent 28-week open-label treatment period receiving dorzagliatin 75mg twice daily. The primary efficacy endpoint is evaluated at the conclusion of the first 24 weeks. The trial is being conducted in 72 clinical sites across China led by Professor Wenying Yang at China-Japan Friendship Hospital. (NCT03141073).
About Dorzagliatin
Dorzagliatin is an investigational first-in-class, dual-acting glucokinase activator, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in patients with Type 2 diabetes. By addressing the defect of the glucose sensor function of glucokinase, dorzagliatin has the potential to restore the impaired glucose homeostasis state of patients with Type 2 diabetes and serve as a first-line standard-of-care therapy for the treatment of the disease, or as a cornerstone therapy when taken in combination with currently approved anti-diabetes drugs.
About Hua Medicine
Hua is a leading, clinical-stage innovative drug development company in China focused on developing novel therapies for the treatment of diabetes. Founded by an experienced group of entrepreneurs and international investment firms, Hua advanced a first-in-class oral drug for the treatment of Type 2 diabetes into NDA-enabling stage and is currently evaluating the therapy in adults with diabetes in two Phase III trials in China and various earlier stage clinical trials in China and the United States. Dorzagliatin has achieved its first primary endpoint in a Phase III monotherapy trial. The Company has initiated product life-cycle management studies of this novel diabetes therapy and advanced its use in personalized diabetes care. Hua Medicine is working closely with disease experts and regulatory agencies in China and across the world to advance diabetes care solutions for patients worldwide.
For more information
Hua Medicine
Website: www.huamedicine.com
Investors
Email: ir@huamedicine.com
Media
Email: pr@huamedicine.com
Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com
source http://www.acnnewswire.com/press-release/english/59982/
- Met the primary efficacy and safety endpoints in the double-blinded placebo-controlled and randomized 24-week trial
- Dorzagliatin again demonstrated fast onset, potent and sustained HbA1c reduction of 1.02% from baseline at 24-week, and is superior over placebo treated group by 0.66% with a p-value less than 0.0001, in T2D patients whose blood glucose cannot be controlled with the maximum dose of metformin (1500mg/day).
- High response rate was observed in the treatment group with 44.4% of patients having achieved HbA1c level below 7% at 24-week
- Statistically significant improvements in HbA1c response rate, HOMA2-beta and HOMA2-IR, 2hPPG and FPG, were observed in the dorzagliatin-treated group over the placebo group
- Clinically significant hypoglycemia incidence rate is less than 1% in the 24-week treatment period
- In the 24-week treatment period, dorzagliatin demonstrated a well-tolerated and good safety profile. There was no drug-related SAE, nor severe hypoglycemia reported
In 766 Type 2 diabetes patients whose blood glucose cannot be controlled with the maximum tolerated dose of equal or greater than 1500 mg/day of metformin, dorzagliatin demonstrated fast onset, potent and sustained HbA1c reduction of 1.02% (least squares mean) from baseline at 24-week, as compared to a reduction of 0.36% (least squares mean) from baseline for the placebo group (p-value less than 0.0001, 95% CI between -0.79 to -0.53).
The American Diabetes Association (ADA) treatment target of HbA1c below 7.0%was achieved by 44.4% of subjects on dorzagliatin and metformin, compared to 10.7% of subjects who received metformin only. Patients treated with dorzagliatin demonstrated statistically significant improvement of HOMA2-beta, HOMA2-IR, 2hPPG and FPG over those in the placebo group.
In the 24-week period, dorzagliatin continued to exhibit a safe and well-tolerated clinical profile. There was less than 1% hypoglycemia with blood glucose < 3 mmol/L during the 24-week treatment period. There was no drug-related SAE, nor severe hypoglycemia reported.
"I am very pleased to see dorzagliatin provided very good glycemic control in the metformin-failed Type 2 diabetes patients in China," said Dr. Wenying Yang of the China-Japan Friendship Hospital and lead principal investigator of HMM0302 clinical study. "It offers a new solution to many patients whose blood glucose cannot be controlled with maximum tolerated dose of metformin, the first line therapy currently used for T2D treatment worldwide. I am very impressed by the determination and execution of Hua Medicine during the clinical trials, consistent with global standards, which leads to the high quality results in the 24-week period of HMM0302 trial."
"I am very excited to see the success in the HMM0302 clinical study. It will expand dorzagliatin into a very large patient population and help millions of T2D patients who failed in metformin treatment. It further supports our strategy to add dorzagliatin as a cornerstone therapy to current therapies including metformin, and DPP-IV inhibitors or SGLT-2 inhibitors, as well as GLP-1 and insulin. It will immediately expand our drug product pipeline based on the combination therapies," said Dr. Li Chen, CEO of Hua Medicine. "Through repairing the glucose sensor and improving the glucose sensitivity which addressed the underlying cause of T2D, dorzagliatin provides the synergy with existing antidiabetic medicines to better control diabetes. This is the first step to systematically address the heterogenic nature of T2D and provide a solution in personalized diabetes care."
Hua Medicine is planning to file an NDA in China after completing the second stage of the HMM0302 52-week study and developing one or more partnership to commercialize dorzagliatin in China and the rest of the world.
HMM0302 study design
HMM0302 Study is a randomized, double-blind, placebo-controlled Phase III study in 766 Type 2 diabetes patients inadequately glycemic controlled with metformin. Subjects are treated with metformin (Glucophage) at 1500mg/day as basic therapy throughout the whole 52-week treatment period. Patients are given twice-daily doses of dorzagliatin (75mg) or placebo, randomized on a 1:1 ratio. The clinical study evaluates the efficacy and safety of dorzagliatin during 24 weeks of double-blinded treatment, followed by a subsequent 28-week open-label treatment period receiving dorzagliatin 75mg twice daily. The primary efficacy endpoint is evaluated at the conclusion of the first 24 weeks. The trial is being conducted in 72 clinical sites across China led by Professor Wenying Yang at China-Japan Friendship Hospital. (NCT03141073).
About Dorzagliatin
Dorzagliatin is an investigational first-in-class, dual-acting glucokinase activator, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in patients with Type 2 diabetes. By addressing the defect of the glucose sensor function of glucokinase, dorzagliatin has the potential to restore the impaired glucose homeostasis state of patients with Type 2 diabetes and serve as a first-line standard-of-care therapy for the treatment of the disease, or as a cornerstone therapy when taken in combination with currently approved anti-diabetes drugs.
About Hua Medicine
Hua is a leading, clinical-stage innovative drug development company in China focused on developing novel therapies for the treatment of diabetes. Founded by an experienced group of entrepreneurs and international investment firms, Hua advanced a first-in-class oral drug for the treatment of Type 2 diabetes into NDA-enabling stage and is currently evaluating the therapy in adults with diabetes in two Phase III trials in China and various earlier stage clinical trials in China and the United States. Dorzagliatin has achieved its first primary endpoint in a Phase III monotherapy trial. The Company has initiated product life-cycle management studies of this novel diabetes therapy and advanced its use in personalized diabetes care. Hua Medicine is working closely with disease experts and regulatory agencies in China and across the world to advance diabetes care solutions for patients worldwide.
For more information
Hua Medicine
Website: www.huamedicine.com
Investors
Email: ir@huamedicine.com
Media
Email: pr@huamedicine.com
Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com
source http://www.acnnewswire.com/press-release/english/59982/
Black Wealth Matters Welcomes SEC Internal Investigation Into Racist Attack on Solomon Ali; Demands Transparency and Accountability
ATLANTA, GA, Jul 1, 2020 - (ACN Newswire) - Black Wealth Matters, a group of black entrepreneurs and artists dedicated to economic inclusion for African Americans today welcomed news that the SEC is conducting a full internal investigation into the racist attacks by the agency on entrepreneur and philanthropist Solomon Ali after the agency conducted an initial review of the facts of the case and after speaking with Black Wealth Matters members. The investigation will be led by Nicholas Padilla, Deputy Inspector General for Investigations and by Tracey MacNeill, the SEC's Ombudsman.
Arletta Saafir, a spokesperson for Black Wealth Matters, had the following statement:
"We appreciate our dialogue with Nick Padilla and Tracey MacNeill at the SEC and we are hopeful that their investigation will be impartial, fair, and transparent. Any objective observer who reviews the intimidation tactics used by the SEC, their misleading statements, and their very reason for targeting Solomon in the first place will see the SEC's complaint against him for what it is: a racist persecution. We are curious to learn to what degree racial bias at the SEC is systemic thus we urge the investigation to focus on broader trends of racial bias at the agency. Moreover, we want to know if the higher-ups such as Jay Clayton and the commissioners approved this racist attack. We urge Mr. Padilla and Ms. MacNeill to publish the full details of their investigation online so that the public, Members of Congress, and the media can see exactly how and why Solomon was targeted in such an abusive manner."
A video about the SEC's targeting Solomon Ali can be viewed at https://bit.ly/standwithsolomon
More information can be found at www.supportsolomon.org
PRESS CONTACT:
Arletta Saafir
T: +1 (470) 317-3877
E: standbysolomon@gmail.com
www.SupportSolomon.org
This press release was issued through EmailWire.com. For more information, go to http://www.emailwire.com
Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com
source http://www.acnnewswire.com/press-release/english/59971/
Arletta Saafir, a spokesperson for Black Wealth Matters, had the following statement:
"We appreciate our dialogue with Nick Padilla and Tracey MacNeill at the SEC and we are hopeful that their investigation will be impartial, fair, and transparent. Any objective observer who reviews the intimidation tactics used by the SEC, their misleading statements, and their very reason for targeting Solomon in the first place will see the SEC's complaint against him for what it is: a racist persecution. We are curious to learn to what degree racial bias at the SEC is systemic thus we urge the investigation to focus on broader trends of racial bias at the agency. Moreover, we want to know if the higher-ups such as Jay Clayton and the commissioners approved this racist attack. We urge Mr. Padilla and Ms. MacNeill to publish the full details of their investigation online so that the public, Members of Congress, and the media can see exactly how and why Solomon was targeted in such an abusive manner."
A video about the SEC's targeting Solomon Ali can be viewed at https://bit.ly/standwithsolomon
More information can be found at www.supportsolomon.org
PRESS CONTACT:
Arletta Saafir
T: +1 (470) 317-3877
E: standbysolomon@gmail.com
www.SupportSolomon.org
This press release was issued through EmailWire.com. For more information, go to http://www.emailwire.com
Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com
source http://www.acnnewswire.com/press-release/english/59971/
Subscribe to:
Posts (Atom)